




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : <b>A61K 39/395, A61J 1/00</b>	A2	(11) International Publication Number: <b>WO 97/26912</b> (43) International Publication Date: <b>31 July 1997 (31.07.97)</b>
(21) International Application Number: <b>PCT/US97/00492</b>		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: <b>11 January 1997 (11.01.97)</b>		
(30) Priority Data: <b>08/589,982</b> 23 January 1996 (23.01.96) US		
(71) Applicants: GENENTECH, INC. [US/US]; 460 Point San Bruno Boulevard, South San Francisco, CA 94080-4990 (US). UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE [US/US]; 85 South Prospect Street, Burlington, VT 05405-0160 (US).		
(72) Inventors: BEDNAR, Martin, M.; 33 Bartlett Bay Road, South Burlington, VT 05403 (US). GROSS, Cordell, E.; 1001 Dorset Street, South Burlington, VT 05403 (US). THOMAS, G., Roger; 812 Park Avenue, Burlingame, CA 94010 (US).		
(74) Agents: HASAK, Janet, E. et al.; Genentech, Inc., 460 Point San Bruno Boulevard, South San Francisco, CA 94080-4990 (US).		

(54) Title: ANTI-CD18 ANTIBODIES FOR USE AGAINST STROKE



## (57) Abstract

A method for improving clinical outcome in focal ischemic stroke in a mammal by increasing cerebral blood flow and/or reducing infarct size is described which involves administering an effective amount of an anti-CD18 antibody to the mammal, in the absence of removal of the arterial obstruction.

***FOR THE PURPOSES OF INFORMATION ONLY***

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Larvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

ANTI-CD 18 ANTIBODIES FOR USE AGAINST STROKE

This invention was made with United States government support under grant NS31008 and NS28708 awarded by the National Institutes of Health. The United States government has certain rights in the invention.

**BACKGROUND OF THE INVENTION****Field of the Invention**

This invention relates generally to the use of anti-CD18 antibodies for treating stroke. In particular, it relates to the use of anti-CD18 antibodies for improving clinical outcome by increasing cerebral blood flow and/or reducing infarct size in focal ischemic stroke caused by obstruction of a main cerebral artery.

**Description of Related Art**

Stroke is a general term for acute brain damage resulting from disease of blood vessels. This presents a serious problem to society, with about 500,000 people dying from or becoming permanently disabled by stroke in the United States each year. Stroke can be classified into two main categories: hemorrhagic stroke (resulting from leakage of blood outside of the normal blood vessels) and ischemic stroke (cerebral ischemia due to lack of blood supply); this application is primarily concerned with the latter.

The three main mechanisms of ischemic stroke are thrombosis, embolism and systemic hypoperfusion (with resultant ischemia and hypoxia). In each of these types of stroke, the area of the brain that dies as a result of the lack of blood supply thereto is called an infarct. Obstruction of a cerebral artery resulting from a thrombus which has built up on the wall of a brain artery is generally called *cerebral thrombosis*. In *cerebral embolism*, the occlusive material blocking the cerebral artery arises downstream in the circulation (e.g. an embolus is carried to the cerebral artery from the heart). Because it is difficult to discern whether a stroke is caused by thrombosis or embolism, the term *thromboembolism* is used to cover both these types of stroke. *Systemic hypoperfusion* may arise as a consequence of decreased blood levels, reduced hematocrit, low blood pressure or inability of the heart to pump blood adequately.

When symptoms of stroke last less than 24 hours and the patient recovers completely, the patient is said to have undergone a transient ischemic attack (TIA). The symptoms of TIA are a temporary impairment of speech, vision, sensation or movement. Because a TIA is often thought to be a prelude to full-scale stroke, patients having suffered a TIA are candidates for prophylactic stroke therapy with anticoagulation agents (e.g., coumarin and heparin) or antiplatelet agents (such as aspirin and ticlopidine) for example.

Thrombolytic agents, such as tissue plasminogen activator (t-PA), have been used in the treatment of thromboembolic stroke. These molecules function by lysing the thrombus causing the ischemia. Such drugs are believed to be most useful if administered as soon as possible after acute stroke (preferably within 3 hours) in order to at least partially restore cerebral blood flow in the ischemic region and to sustain neuronal viability. In that such drugs exacerbate bleeding, their use in hemorrhagic stroke is contra-indicated.

A family of adhesion glycoproteins present on leukocytes is called the *integrin* family. This integrin family includes LFA-1 (CD11a/CD18), Mac-1 (CD11b/CD18) and p150,95 (CD11c/CD18). A further member of this family CD11d/CD18 has recently been reported. Danilenko *et al.*, *J. Immunol.* 155:35-44 (1995). Each of these heterodimers has a unique  $\alpha$ -chain (CD11a, b, c or d) and the invariant  $\beta$ -chain (CD18). CD18 integrins located on leukocytes may bind to intercellular adhesion molecule-1 (ICAM-1) which is expressed on vascular endothelium and other cells, thereby mediating leukocyte adhesion and transendothelial migration.

It has been noted that CD11a and CD18 are upregulated in leukocytes from patients who have undergone ischemic stroke or a TIA. Kim *et al.*, *J. Neurolog. Sci.* 128(1):45-50 (1995). Schroeter *et al.*, *J. Neuroimmunology* 55(2):195-203 (1994) found that increased expression of ICAM-1 on vessels and leukocytes occurred following cerebral ischemia induced by permanent occlusion of the middle cerebral artery (MCA) in the rat.

The role of cell adhesion molecules in brain injury following transient MCA occlusion in the rat has been studied (Matsuo *et al.*, *Brain Research* 656:344-352 (1994)). Matsuo *et al.* inserted a nylon thread from the lumen of the external carotid artery (ECA) to that of the right internal carotid artery (ICA) in order to occlude the origin of the right MCA. The occlusion was transient; after 1 hour, the nylon thread was removed to allow complete reperfusion of the ischemic area via the right common carotid artery (CCA). Anti-CD11a (WT1), anti-CD18 (WT3) and anti-ICAM-1 (IA29) antibodies were administered before ischemia and immediately after reperfusion. These researchers found that treatment with individual antibodies against cell adhesion molecules reduced edema formation, infarct size and neutrophil accumulation following reperfusion.

Others have investigated the effects of antibodies against cell adhesion molecules in such transient stroke models. Zhang *et al.*, *Brain Research* 698:79-85 (1995) studied the effects of anti-CD11b and anti-CD18 monoclonal antibodies in ischemia/reperfusion injury, wherein the antibodies were administered upon and after transient MCA occlusion (the origin of the MCA was transiently blocked with a surgical nylon filament). Mori *et al.*, *Stroke* 23(5): 712-718 (1992) studied the effects of the anti-CD18 IB4 antibody in their baboon model of reversible MCA occlusion. In this model, arterial obstruction was achieved by inflating an extrinsic MCA balloon to 100 $\mu$ l. Reperfusion occurred following balloon deflation. See, also, Chopp *et al.*, *Stroke* 25(4):869-876 (1994) and Chen *et al.*, *Annals of Neurology* 35(4): 458-463 (1994) concerning an anti-CD11b antibody in a transient cerebral ischemia model. Chopp *et al.*, and Chen *et al.*, advanced a surgical nylon suture into the ICA to block the origin of the MCA. Reperfusion was accomplished by withdrawing the suture until the tip cleared the ICA lumen.

Takeshima *et al.*, *Stroke*, 23(2):247-252 (1992) found that the anti-CD18 antibody 60.3 did not afford protection from severe focal ischemia and reperfusion in a transient focal cerebral ischemia model in cats. Takeshima *et al.* used a microvascular clip to occlude the MCA and occluded CCAs by tightening previously placed ligatures.

Lindsberg *et al.*, *J. Neurosurg.* 82:269-277 (1995) subjected rabbits to severe spinal cord ischemia (by inflating the balloon of a catheter tip which had been introduced in the abdominal aorta) followed by 30 minutes of reperfusion at which time either: (1) vehicle, (2) anti-CD18 antibody, or (3) anti-CD18 antibody and platelet-activating factor (PAF) antagonist were administered to the animals. Recovery of motor function was improved by the anti-CD18 antibody, but no further improvement was induced by the PAF antagonist.

It has been observed that while an anti-CD18 antibody reduced neurologic deficits in the reversible spinal cord model (involving a snare ligature occluding device), it was unable to do so in an irreversible microsphere model. Clark *et al.*, *Stroke* 22(7): 877-883 (1991). Clark *et al.* conclude that leukocytes potentiate their effect in central nervous system injury via reperfusion injury. With respect to anti-CD11b antibodies, Chopp *et al.*, *Stroke* 25(1):267 (1994) report that benefit from administration of such antibodies was observed under conditions of transient, but not permanent, MCA occlusion in rats. See, also, Jiang *et al.*, *Neuroscience*

*Research Communications* 15(2):85-93 (1994). Clark *et al.*, *J. Neurosurg* 75(4):623-627 (1991) also observe that while anti-ICAM-1 produced a significant reduction in neurological deficits in the reversible spinal cord ischemia model, such therapeutic benefit was not seen in the irreversible brain ischemia model. Similar findings in relation to anti-ICAM-1 antibodies have also been reported by Zhang *et al.*, *Stroke* 26(8):1438-1442 (1995).

5 Bowes *et al.*, *Neurology* 45:815-819 (1995) evaluated the ability of monoclonal antibodies directed against ICAM-1 and CD18 to enhance the efficacy of thrombolysis in a rabbit cerebral embolism stroke model. In this model, numerous small blood clots (formed by fragmenting a clot with a tissue homogenizer) were injected into the rabbit's carotid circulation in order to achieve embolization. Neurologic function in each animal was evaluated 18 hours following embolization on a three point scale: (1) normal activity; (2) abnormal activity; 10 or (3) death. The amount of clot necessary to produce permanent neurologic damage in 50% of the rabbits ( $ED_{50}$ ) was determined for each treatment group. Bowes *et al.* found that when administration of anti-CD18 or anti-ICAM-1 was delayed until 15 or 30 minutes after embolization, a statistically significant improvement in neurologic function was *not* observed. See also Bowes *et al.*, *Experimental Neurology* 119(2):215-219 (1993) in relation to earlier work by this group regarding anti-ICAM-1 and t-PA in their rabbit cerebral embolism stroke 15 model.

20 Bednar *et al.*, *Stroke* 23(1):152 (1992) describe a rabbit model of thromboembolic stroke wherein the arterial occlusion (an autologous blood clot delivered to the anterior cerebral circulation) is not removed during the experiment. Rabbits received either anti-CD18 antibody IB4 (1mg/kg), or vehicle, 30 minutes following the thromboembolic event. Following embolization, the animals were studied for a total of 4 hours, including an initial 45 minutes of systemic hypotension. No statistically significant difference in cerebral blood flow (CBF) or infarct size between IB4 and vehicle treated animals was seen. However, IB4 did attenuate intracranial hypertension in this model.

25 It is an object of the present invention to provide a method for improving clinical outcome in acute ischemic stroke by increasing cerebral blood flow and/or reducing infarct size. Furthermore, it is an object of the invention to provide an alternative to thrombolytic therapy for treating thromboembolic stroke, particularly where thrombolytic therapy has been unsuccessful or is contra-indicated, as is the case where the patient to be treated is taking aspirin, or where the time delay from the onset of stroke to diagnosis is such that thrombolytic therapy is not recommended. Other objects will be apparent from the description which follows.

#### SUMMARY OF THE INVENTION

30 This application is based on the unexpected finding that anti-CD18 antibodies can lead to a significant increase in cerebral blood flow and/or reduction in brain infarct size in focal ischemic stroke, in the absence of removal of the arterial obstruction.

Accordingly, the invention provides a method for treating stroke in a mammal (e.g. focal ischemic stroke caused by obstruction of a main cerebral artery) which comprises the step of administering an amount of 35 CD18 antagonist and/or CD11b antagonist to the mammal which is effective for increasing cerebral blood flow and/or reducing cerebral infarct size in the mammal. In the method, the arterial obstruction (generally a single thrombus or embolus) is not removed by mechanical means (e.g. by surgically removing the obstruction) or chemical means (e.g. by using a thrombolytic agent to dissolve the arterial obstruction). Furthermore, the

recipient of the CD18 or CD11b antagonist is not subjected to extraneous systemic hypotension (e.g., via controlled exsanguination) during the method as was the case in Bednar *et al.*, *Stroke* 23(1):152 (1992).

Preferably the antagonist is an anti-CD18 antibody, such as a humanized F(ab')<sub>2</sub> fragment. Conveniently, the antagonist is administered to the mammal in the form of a pharmaceutically acceptable formulation, such as those elaborated in more detail herein.

The preferred mode of administration of the antagonist is by bolus intravenous dosage. In certain embodiments of the invention, the antagonist may be administered at least once a time between about 15 minutes to about 20 hours and preferably between about 30 minutes to about 12 hours from the onset of focal ischemic stroke. Single or multiple dosages may be given. Alternatively, or in addition, the antagonist may be administered via continuous infusion:

In another aspect, the invention relates to a method for treating ischemic stroke caused by systemic hypoperfusion or hypoxia in a mammal (e.g. resulting from cardiac arrest or drowning) which comprises the step of administering a therapeutically effective amount of CD11b antagonist and/or CD18 antagonist to the mammal. The preferred antagonist for use in this method is an anti-CD18 antibody. Preferably, the method results in an increase in cerebral blood flow and a decrease in infarct size resulting from the systemic hypoperfusion.

In yet another embodiment, the invention provides a method for increasing cerebral blood flow and/or reducing infarct size in focal ischemic stroke caused by obstruction of a main cerebral artery which comprises the step of administering a therapeutically effective amount of CD18 and/or CD11b antagonist to the mammal at least once at a time more than 15 mins (e.g. more than 30 mins) and preferably less than 24 hours from the onset of focal ischemic stroke in the mammal. In the method, the mammal being treated is not subjected to extraneous systemic hypotension as described in Bednar *et al.*, *Stroke* 23(1):152 (1992). Preferably the antagonist is an anti-CD18 antibody which is administered at least once at a time between about 30 minutes to about 12 hours from the onset of focal ischemic stroke.

According to the method of the previous paragraph, a therapeutically effective amount of a thrombolytic agent (such as t-PA) may be co-administered to the mammal either before, after, or simultaneously with, the CD11b or CD18 antagonist. Preferably, the antagonist is administered to the mammal prior to administration of the thrombolytic agent. According to this method, the thrombolytic agent may be administered to the mammal more than about 3 hours after the onset of ischemic stroke (e.g., at least once within about 3-8 hours and preferably within about 3-5 hours from the onset of stroke). The thrombolytic agent may be administered by one or more bolus doses or by continuous infusion, for example.

The invention also provides articles of manufacture and kits for use in the above methods.

#### Brief Description of the Drawings

Fig. 1 is a bar graph depicting brain infarct size (% hemisphere infarcted) in embolized rabbits following treatment with MHM23 (anti-CD18) and t-PA (n=5); MHM23 alone (n=5); t-PA alone (n=10) or saline solution control (n=10) as described in Example 1 (mean +/- standard error of the mean).

Fig. 2 depicts regional cerebral blood flow (CBF; cc/100gm/min) over time in embolized rabbits following treatment with MHM23 (anti-CD18) and t-PA (n=5); MHM23 alone (n=5); t-PA alone (n=10) or saline solution control (n=10) as described in Example 1. MHM23 or saline solution control was administered

1 hour following embolization. t-PA or saline solution control was administered by continuous infusion over hours 3-5 following embolization (mean +/- standard error of the mean).

Fig. 3 illustrates intracranial pressure (ICP; mm Hg) in embolized rabbits following treatment with MHM23 (anti-CD18) and t-PA (n=5); MHM23 alone (n=5); t-PA alone (n=10) or saline solution control (n=10) as described in Example 1. MHM23 or saline solution control was administered 1 hour following embolization. t-PA or saline solution control was administered by continuous infusion over hours 3-5 following embolization (mean +/- standard error of the mean).

Figs. 4A-B depict an alignment of the relevant portions of the consensus amino acid sequences of the human IgG<sub>1</sub> CH1 domain (SEQ ID NO: 1), the human IgG<sub>2</sub> CH1 domain (SEQ ID NO: 2), the human IgG<sub>3</sub> CH1 domain (SEQ ID NO: 3), the human IgG<sub>4</sub> CH1 domain (SEQ ID NO: 4), the human κ C<sub>L</sub> domain (SEQ ID NO: 5), and the human λ C<sub>L</sub> domain (SEQ ID NO: 6), in alignment with the Fabv1b variant derived from an anti-CD18 antibody (SEQ ID NO: 7). In Figs. 4A-B, amino acid residues and/or positions of interest and of most importance for use as salvage receptor binding epitopes within the sequence of Fabv1b (*i.e.*, SEQ ID NOS: 8 and 9) are designated by underlining and asterisks, respectively.

#### Detailed Description of the Preferred Embodiments

##### I. Definitions

"Focal ischemic stroke" is defined herein as damage to the brain caused by interruption of the blood supply to a region thereof. The focal ischemic stroke of interest herein is generally caused by obstruction of any one or more of the "main cerebral arteries" (*e.g.*, middle cerebral artery, anterior cerebral artery, posterior cerebral artery, internal carotid artery, vertebral artery or basilar artery), as opposed to secondary arteries or arterioles. The "arterial obstruction" is generally a single embolus or thrombus. Hence, focal ischemic stroke as defined herein is distinguished from the cerebral embolism stroke model of Bowes *et al.*, *Neurology* 45:815-819 (1995) in which a plurality of clot particles occlude secondary arteries or arterioles.

The expression "in the absence of removal of the arterial obstruction" when used throughout this application means that the arterial obstruction is essentially not removed by mechanical means (for example, by physically removing the obstruction as described in the transient stroke models described above) or by chemical means (such as removal of a thrombus or embolus using a thrombolytic agent; see, *e.g.*, Bowes *et al.*, *Neurology* 45:815-819 (1995)) prior to a therapeutic benefit achieved by administration of the CD18 or CD11b antagonist (*i.e.*, the increase in cerebral blood flow and/or the reduction in infarct size). However, this term would encompass situations wherein the arterial obstruction is slightly reduced in size as a consequence of endogenous thrombolytic molecules dissolving part of the thrombus/embolus, provided that at least some (*e.g.*, about 50% and preferably about 80%) of the arterial obstruction remains intact following any such size reduction.

By "increasing cerebral blood flow or reducing infarct size" is meant the act of improving clinical outcome by inducing a statistically or physiologically significant increase in cerebral blood flow and/or a statistically or physiologically significant reduction in infarct size in a treated mammal relative to an untreated mammal as determined using techniques which are well known in the art, such as vascular imaging, for example. Preferably cerebral blood flow as determined 2-4 hours after administration of the antagonist is increased by at least 30% and preferably at least 50% relative to an untreated mammal. Desirably, infarct size measured 48

hours after administration of the antagonist will be 20% less and preferably 50% less than that of an untreated mammal.

The term "CD18 antagonist" when used herein refers to a molecule which binds to CD18 (preferably human CD18) and inhibits or substantially reduces a biological activity of CD18. Normally, the antagonist will block (partially or completely) the ability of a cell (e.g. a neutrophil) expressing the CD18 subunit at its cell surface to bind to endothelium. Non-limiting examples of CD18 antagonists include antibodies, proteins, peptides, glycoproteins, glycopeptides, glycolipids, polysaccharides, oligosaccharides, nucleic acids, bioorganic molecules, peptidomimetics, pharmacological agents and their metabolites, transcriptional and translation control sequences, and the like. In the preferred embodiment of the invention, the CD18 antagonist is an antibody.

Examples of anti-CD18 antibodies include MHM23 (Hildreth *et al.*, *Eur. J. Immunol.* 13:202-208 (1983)); M18/2 (IgG<sub>2a</sub>; Sanches-Madrid *et al.*, *J. Exp. Med.* 158:586 (1983)); H52 (American Type Culture Collection (ATCC) Deposit HB 10160); Mas191c and IOT18 (Vermot Desroches *et al.*, *Scand. J. Immunol.* 33:277-286 (1991)); and NA-8 (WO 94/12214). The preferred antibody is one which binds to the CD18 epitope to which either MHM23 or H52 binds. Preferably the antibody has a high affinity for the CD18 polypeptide.

In preferred embodiments, the antibody has an affinity for the CD18 antigen of about 4nM or less. Preferably, the affinity is about 3nM or less, and most preferably 1nM or less. In certain embodiments, the antibody may bind to a region in the extracellular domain of CD18 which associates with CD11b and the antibody may also dissociate  $\alpha$  and  $\beta$  chains (e.g. the antibody may dissociate the CD11b and CD18 complex as is the case for the MHM23 antibody).

The term "CD11b antagonist" when used herein refers to a molecule which binds to CD11b and inhibits or substantially reduces a biological activity of CD11b. Normally, the antagonist will block (partially or completely) the ability of a cell (e.g. a neutrophil) expressing the CD11b subunit at its cell surface to bind to endothelium. Non-limiting examples of CD11b antagonists include antibodies, proteins, peptides, glycoproteins, glycopeptides, glycolipids, polysaccharides, oligosaccharides, nucleic acids, bioorganic molecules, peptidomimetics, pharmacological agents and their metabolites, transcriptional and translation control sequences, and the like. The preferred CD11b antagonist is an antibody, especially an anti-CD11b antibody which binds human CD11b. Exemplary CD11b antibodies include MY904 (US Patent 4,840,793); 1B6c (see Zhang *et al.*, *Brain Research* 698:79-85 (1995)); CBRN1/5 and CBRM1/19 (WO94/08620).

The term "antibody" is used in the broadest sense and specifically covers monoclonal antibodies, antibody compositions with polyepitopic specificity, bispecific antibodies, diabodies, and single-chain molecules, as well as antibody fragments (e.g., Fab, F(ab')<sub>2</sub>, and Fv), so long as they antagonize the biological activity of CD11b or CD18.

The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to conventional (polyclonal) antibody preparations which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. In addition to their specificity, the monoclonal antibodies are advantageous in that they are synthesized by the

hybridoma culture, uncontaminated by other immunoglobulins. The modifier "monoclonal" indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies to be used in accordance with the present invention may be made by the hybridoma method first described by Kohler *et al.*, *Nature*, 256: 495 (1975), or may be made by recombinant DNA methods (see, e.g., U.S. Patent No. 4,816,567). The "monoclonal antibodies" may also be isolated from phage antibody libraries using the techniques described in Clackson *et al.*, *Nature*, 352:624-628 (1991) and Marks *et al.*, *J. Mol. Biol.*, 222:581-597 (1991), for example.

The monoclonal antibodies herein specifically include "chimeric" antibodies (immunoglobulins) in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity (U.S. Patent No. 4,816,567; Morrison *et al.*, *Proc. Natl. Acad. Sci. USA*, 81:6851-6855 (1984)).

"Humanized" forms of non-human (e.g., murine) antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')<sub>2</sub> or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin. For the most part, humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a complementary-determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity, and capacity. In some instances, Fv framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, humanized antibodies may comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. These modifications are made to further refine and optimize antibody performance. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. For further details, see Jones *et al.*, *Nature*, 321:522-525 (1986); Reichmann *et al.*, *Nature*, 332:323-329 (1988); and Presta, *Curr. Op. Struct. Biol.*, 2:593-596 (1992). The humanized antibody includes a Primatized<sup>TM</sup> antibody wherein the antigen-binding region of the antibody is derived from an antibody produced by immunizing macaque monkeys with the antigen of interest.

"Single-chain Fv" or "sFv" antibody fragments comprise the V<sub>H</sub> and V<sub>L</sub> domains of antibody, wherein these domains are present in a single polypeptide chain. Generally, the Fv polypeptide further comprises a polypeptide linker between the V<sub>H</sub> and V<sub>L</sub> domains which enables the sFv to form the desired structure for antigen binding. For a review of sFv see Pluckthun in *The Pharmacology of Monoclonal Antibodies*, vol. 113, Rosenberg and Moore eds., Springer-Verlag, New York, pp. 269-315 (1994).

The term "diabodies" refers to small antibody fragments with two antigen-binding sites, which fragments comprise a heavy-chain variable domain ( $V_H$ ) connected to a light-chain variable domain ( $V_L$ ) in the same polypeptide chain ( $V_H - V_L$ ). By using a linker that is too short to allow pairing between the two domains on the same chain, the domains are forced to pair with the complementary domains of another chain and create 5 two antigen-binding sites. Diabodies are described more fully in, for example, EP 404,097; WO 93/11161; and Hollinger *et al.*, *Proc. Natl. Acad. Sci. USA*, 90: 6444-6448 (1993).

As used herein, the term "salvage receptor binding epitope" refers to an epitope of the Fc region of an IgG molecule (e.g., IgG<sub>1</sub>, IgG<sub>2</sub>, IgG<sub>3</sub>, and IgG<sub>4</sub>) that is responsible for increasing the *in vivo* serum half-life of the IgG molecule.

10 "Treatment" refers to both therapeutic treatment and prophylactic or preventative measures. Those in need of treatment include those already with the disorder as well as those in which the disorder is to be prevented. This application is mostly concerned with treating those individuals who have been diagnosed as having suffered acute ischemic stroke.

15 "Mammal" for purposes of treatment refers to any animal classified as a mammal, including humans, domestic and farm animals, and zoo, sports, or pet animals, such as dogs, horses, cats, cows, etc. Preferably, the mammal is human.

A "thrombolytic agent" is a molecule which breaks up or dissolves a thrombus. Exemplary thrombolytic agents include streptokinase, acylated plasminogen-streptokinase activator complex (APSAC), urokinase, single-chain urokinase-plasminogen activator (scu-PA), thrombinlike enzymes from snake venoms such as ancrod (Bell, 20 W. "Defibrinogenating enzymes" In Colman *et al.*, (eds): *Hemostasis and Thrombosis* Lippincott, Philadelphia (1987) p. 886), tissue plasminogen activator (t-PA) and biologically active variants of each of the above. The preferred thrombolytic agent is t-PA.

In the context of the present invention, the terms "tissue plasminogen activator" and "t-PA" are used 25 interchangeably and denote extrinsic (tissue type) plasminogen activator having at least two functional domains consisting of a protease domain that is capable of converting plasminogen to plasmin and an N-terminal region believed to be responsible for fibrin binding. These terms therefore include polypeptides containing these functional domains as part of the overall amino acid sequence, irrespective of their source and method of preparation (e.g. these terms cover vampire bat t-PAs as disclosed in EP 352,119). The terms "human tissue 30 plasminogen activator" and "human t-PA" are used interchangeably and denote wild-type human tissue plasminogen activator and functional derivatives thereof. Examples of t-PA functional derivatives include those molecules with extended half-life and improved fibrin specificity as disclosed in WO 93/24635; N-terminally truncated t-PA variants (see EP 382,174); and C84S t-PA described in Suzuki *et al.*, *J. Cardiovasc. Pharmacol.* 22:834-840 (1993), for example.

## II. Modes for Carrying out the Invention

35 The invention provides a method for treating focal ischemic stroke, such as thromboembolic stroke. In particular, cerebral blood flow can be increased and/or infarct size can be reduced in focal ischemic stroke by administering an effective amount of a CD11b and/or CD18 antagonist to the mammal having suffered the stroke. In this method, the arterial obstruction is not removed prior to observation of the therapeutic benefit as defined herein, and as such the method does not require prior administration of a thrombolytic agent to the

mammal in order to remove an embolus/thrombus and thereby increase cerebral blood flow and/or reduce infarct size.

It is contemplated that the CD18 or CD11a antagonist of the present invention will be administered to a patient as soon as possible once the condition of acute ischemic stroke has been diagnosed or is suggested by 5 focal deficit on neurologic examination. Neurologic examination and, optionally, neuroimaging techniques such as computed tomography (CT) and magnetic resonance imaging (MRI) (including diffusion weighted imaging (DWI) and perfusion imaging (PI)); vascular imaging (e.g., duplex scanning and transcranial Doppler ultrasound and laser Doppler); angiography (e.g., computerized digital subtraction angiography (DSA) and MR angiography) as well as other invasive or non-invasive techniques are available for the diagnosis of acute 10 ischemic stroke.

Preferably, the CD18 or CD11a antagonist will be administered at least once or continuously at any time from immediately following to about 24 hours after the onset of stroke. In certain embodiments, the CD18 or CD11a antagonist is first administered to the patient at a time between about 15 minutes (or 30 minutes or 45 minutes) to about 5 hours (or 12 hours or 24 hours) from the onset of stroke. For example, the antagonist may 15 be first administered by bolus dosage as soon as stroke is diagnosed, followed by a subsequent bolus dosage of the antagonist (e.g., 5-24 hours after the initial bolus dosage).

The preferred antagonist for use in the above method is humanized H52 antibody (huH52), especially the huH52 F(ab')<sub>2</sub> antibody fragment.

The sequence of the heavy chain of the huH52 Fab is:

20 EVQLVESGGGLVQPGGSLRLSCATSGYTFTEYTMHWMRQAPGKGLEWVAGINPKNGGTSHNQRF  
MDRFTISVDKSTSTA YMQMNSLRAEDTA VYYCARWRGLNYGFDVRYFDVWGQGT LTVSSASTK  
GPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVWSNSGALTSGVHTFP AVLQSSGLYSLSVVTV  
PSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHT (SEQ ID NO: 10).

The sequence of the light chain of the huH52 Fab is:

25 DIQMTQSPSSLSASVGDRVITCRASQDINNYLNWYQQKPGKAPKLLI YYTSTLHSGVPSRFSGSGSG  
TDYTLTISSLQPEDFATYYCQQGNTLPPTFGQGTKVEIKRTVAAPS VFIFPPSDEQLKSGTASVVCLL  
NNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYLSSTLTSKADYEKHKVY ACEVTHQGL  
SSPVTKSFNRGEC (SEQ ID NO: 11).

In other embodiments, the full length IgG<sub>2</sub> huH52 antibody may be the molecule of choice. The heavy 30 chain of the full length IgG<sub>2</sub> huH52 antibody has the sequence:

EVQLVESGGGLVQPGGSLRLSCATSGYTFTEYTMHWMRQAPGKGLEWVAGINPKNGGTSHNQRF  
MDRFTISVDKSTSTA YMQMNSLRAEDTA VYYCARWRGLNYGFDVRYFDVWGQGT LTVSSASTK  
GPSVFPLAPCSRSTSESTA ALGCLVKDYFPEPVTVWSNSGALTSGVHTFP AVLQSSGLYSLSVVTV  
SSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVT  
35 CVVVVDVSHEDPEVQFNWYVDGMEVHNAKTKPREEQFNSTRVVSVLT VVHQDWLNGKEYKCKV  
SNKGLPAPIEKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN  
YKTPPMULDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK(SEQIDNO:12).

The light chain of the full length IgG<sub>2</sub> huH52 antibody has the sequence:

DIQMTQSPSSLSASVGDRVTITCRASQDINNYLNWYQQKPGKAPKLLIYYTSTLHSGVPSRSGSGSG  
TDYTLTISSLQPEDFATYYCQQGNTLPPTFGQGTKVEIKRTVAAPSVIFPPSDEQLKSGTASVVCLL  
NNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTTLSKADYEKHKVYACEVTHQGL  
SSPVTKSFNRGEC (SEQ ID NO: 13).

5 A description follows as to the production of the preferred antagonists (*i.e.* antibodies), long half-life antagonists, pharmaceutical formulations, modes for administration, as well as kits and articles of manufacture for use in the claimed methods. The description in relation to long half-life antagonists, pharmaceutical formulations and modes for administration is also relevant to the use of thrombolytic agents in certain embodiments of the invention.

10 A. Antibody Preparation

According to the preferred embodiment of the invention, the CD18 or CD11b antagonist is an antibody. Various antibodies which bind to CD18 and CD11b are available in the art. Furthermore, a description follows as to the production of anti-CD18 or anti-CD11b antibodies for use in the treatment of stroke as defined herein.

(i) Polyclonal antibodies.

15 Polyclonal antibodies are generally raised in animals by multiple subcutaneous (sc) or intraperitoneal (ip) injections of the relevant antigen and an adjuvant. It may be useful to conjugate the relevant antigen to a protein that is immunogenic in the species to be immunized, *e.g.*, keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, or soybean trypsin inhibitor using a bifunctional or derivatizing agent, for example, maleimidobenzoyl sulfosuccinimide ester (conjugation through cysteine residues), N-hydroxysuccinimide 20 (through lysine residues), glutaraldehyde, succinic anhydride, SOCl<sub>2</sub>, or R<sup>1</sup>N=C=NR, where R and R<sup>1</sup> are different alkyl groups.

25 Animals are immunized against the antigen, immunogenic conjugates, or derivatives by combining 1 mg or 1 µg of the peptide or conjugate (for rabbits or mice, respectively) with 3 volumes of Freund's complete adjuvant and injecting the solution intradermally at multiple sites. One month later the animals are boosted with 1/5 to 1/10 the original amount of peptide or conjugate in Freund's complete adjuvant by subcutaneous injection at multiple sites. Seven to 14 days later the animals are bled and the serum is assayed for antibody titer. Animals are boosted until the titer plateaus. Preferably, the animal is boosted with the conjugate of the same antigen, but conjugated to a different protein and/or through a different cross-linking reagent. Conjugates also can be made in recombinant cell culture as protein fusions. Also, aggregating agents such as alum are suitably used to 30 enhance the immune response.

(ii) Monoclonal antibodies.

35 Monoclonal antibodies are obtained from a population of substantially homogeneous antibodies, *i.e.*, the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Thus, the modifier "monoclonal" indicates the character of the antibody as not being a mixture of discrete antibodies.

For example, the monoclonal antibodies may be made using the hybridoma method first described by Kohler *et al.*, *Nature*, 256:495 (1975), or may be made by recombinant DNA methods (U.S. Patent No. 4,816,567).

In the hybridoma method, a mouse or other appropriate host animal, such as a hamster, is immunized as hereinabove described to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the protein used for immunization. Alternatively, lymphocytes may be immunized *in vitro*. Lymphocytes then are fused with myeloma cells using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding, *Monoclonal Antibodies: Principles and Practice*, pp.59-103 (Academic Press, 1986)).

The hybridoma cells thus prepared are seeded and grown in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, parental myeloma cells. For example, if the parental myeloma cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine (HAT medium), which substances prevent the growth of HGPRT-deficient cells.

Preferred myeloma cells are those that fuse efficiently, support stable high-level production of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. Among these, preferred myeloma cell lines are murine myeloma lines, such as those derived from MOPC-21 and MPC-11 mouse tumors available from the Salk Institute Cell Distribution Center, San Diego, California USA, and SP-2 cells available from the American Type Culture Collection, Rockville, Maryland USA. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies (Kozbor, *J. Immunol.*, 133:3001 (1984); Brodeur *et al.*, *Monoclonal Antibody Production Techniques and Applications*, pp. 51-63 (Marcel Dekker, Inc., New York, 1987)).

Culture medium in which hybridoma cells are growing is assayed for production of monoclonal antibodies directed against the antigen. Preferably, the binding specificity of monoclonal antibodies produced by hybridoma cells is determined by immunoprecipitation or by an *in vitro* binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA).

The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson *et al.*, *Anal. Biochem.*, 107:220 (1980).

After hybridoma cells are identified that produce antibodies of the desired specificity, affinity, and/or activity, the clones may be subcloned by limiting dilution procedures and grown by standard methods (Goding, *Monoclonal Antibodies: Principles and Practice*, pp.59-103 (Academic Press, 1986)). Suitable culture media for this purpose include, for example, D-MEM or RPMI-1640 medium. In addition, the hybridoma cells may be grown *in vivo* as ascites tumors in an animal.

The monoclonal antibodies secreted by the subclones are suitably separated from the culture medium, ascites fluid, or serum by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.

DNA encoding the monoclonal antibodies is readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). The hybridoma cells serve as a preferred source of such DNA. Once isolated, the DNA may be placed into expression vectors, which are then transfected into host cells such as *E. coli* cells, simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells.

Review articles on recombinant expression in bacteria of DNA encoding the antibody include Skerra *et al.*, *Curr. Opinion in Immunol.*, 5:256-262 (1993) and Plückthun, *Immunol. Revs.*, 130:151-188 (1992).

In a further embodiment, antibodies or antibody fragments can be isolated from antibody phage libraries generated using the techniques described in McCafferty *et al.*, *Nature*, 348:552-554 (1990). Clackson *et al.*,

5 *Nature*, 352:624-628 (1991) and Marks *et al.*, *J. Mol. Biol.*, 222:581-597 (1991) describe the isolation of murine and human antibodies, respectively, using phage libraries. Subsequent publications describe the production of high affinity (nM range) human antibodies by chain shuffling (Marks *et al.*, *Bio/Technology*, 10:779-783 (1992)), as well as combinatorial infection and *in vivo* recombination as a strategy for constructing very large phage libraries (Waterhouse *et al.*, *Nuc. Acids. Res.*, 21:2265-2266 (1993)). Thus, these techniques are viable

10 alternatives to traditional monoclonal antibody hybridoma techniques for isolation of monoclonal antibodies.

The DNA also may be modified, for example, by substituting the coding sequence for human heavy- and light-chain constant domains in place of the homologous murine sequences (U.S. Patent No. 4,816,567; Morrison, *et al.*, *Proc. Natl Acad. Sci. USA*, 81:6851 (1984)), or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide.

15 Typically such non-immunoglobulin polypeptides are substituted for the constant domains of an antibody, or they are substituted for the variable domains of one antigen-combining site of an antibody to create a chimeric bivalent antibody comprising one antigen-combining site having specificity for an antigen and another antigen-combining site having specificity for a different antigen.

20 Chimeric or hybrid antibodies also may be prepared *in vitro* using known methods in synthetic protein chemistry, including those involving crosslinking agents. For example, immunotoxins may be constructed using a disulfide-exchange reaction or by forming a thioether bond. Examples of suitable reagents for this purpose include iminothiolate and methyl-4-mercaptopurylimidate.

(iii) *Humanized and human antibodies.*

25 Methods for humanizing non-human antibodies are well known in the art. Generally, a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These non-human amino acid residues are often referred to as "import" residues, which are typically taken from an "import" variable domain. Humanization can be essentially performed following the method of Winter and co-workers (Jones *et al.*, *Nature*, 321:522-525 (1986); Riechmann *et al.*, *Nature*, 332:323-327 (1988); Verhoeyen *et al.*, *Science*, 239:1534-1536 (1988)), by substituting rodent CDRs or CDR sequences for the corresponding 30 sequences of a human antibody. Accordingly, such "humanized" antibodies are chimeric antibodies (U.S. Patent No. 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.

35 The choice of human variable domains, both light and heavy, to be used in making the humanized antibodies is very important to reduce antigenicity. According to the so-called "best-fit" method, the sequence of the variable domain of a rodent antibody is screened against the entire library of known human variable-domain sequences. The human sequence which is closest to that of the rodent is then accepted as the human framework (FR) for the humanized antibody (Sims *et al.*, *J. Immunol.*, 151:2296 (1993); Chothia *et al.*, *J. Mol.*

*Biol.*, 196:901 (1987)). Another method uses a particular framework derived from the consensus sequence of all human antibodies of a particular subgroup of light or heavy chains. The same framework may be used for several different humanized antibodies (Carter *et al.*, *Proc. Natl. Acad. Sci. USA*, 89:4285 (1992); Presta *et al.*, *J. Immunol.*, 151:2623 (1993)).

5 It is further important that antibodies be humanized with retention of high affinity for the antigen and other favorable biological properties. To achieve this goal, according to a preferred method, humanized antibodies are prepared by a process of analysis of the parental sequences and various conceptual humanized products using three-dimensional models of the parental and humanized sequences. Three-dimensional immunoglobulin models are commonly available and are familiar to those skilled in the art. Computer programs  
10 are available which illustrate and display probable three-dimensional conformational structures of selected candidate immunoglobulin sequences. Inspection of these displays permits analysis of the likely role of the residues in the functioning of the candidate immunoglobulin sequence, i.e., the analysis of residues that influence the ability of the candidate immunoglobulin to bind its antigen. In this way, FR residues can be selected and combined from the recipient and import sequences so that the desired antibody characteristic, such as increased  
15 affinity for the target antigen(s), is achieved. In general, the CDR residues are directly and most substantially involved in influencing antigen binding.

Alternatively, it is now possible to produce transgenic animals (e.g., mice) that are capable, upon immunization, of producing a full repertoire of human antibodies in the absence of endogenous immunoglobulin production. For example, it has been described that the homozygous deletion of the antibody heavy-chain joining 20 region ( $J_H$ ) gene in chimeric and germ-line mutant mice results in complete inhibition of endogenous antibody production. Transfer of the human germ-line immunoglobulin gene array in such germ-line mutant mice will result in the production of human antibodies upon antigen challenge. See, e.g., Jakobovits *et al.*, *Proc. Natl. Acad. Sci. USA*, 90:2551 (1993); Jakobovits *et al.*, *Nature*, 362:255-258 (1993); Bruggermann *et al.*, *Year in Immuno.*, 7:33 (1993). Human antibodies can also be derived from phage- display libraries (Hoogenboom *et al.*, *J. Mol. Biol.*, 227:381 (1991); Marks *et al.*, *J. Mol. Biol.*, 222:581-597 (1991)).  
25

(iv) Bispecific antibodies

Bispecific antibodies (BsAbs) are antibodies that have binding specificities for at least two different epitopes. Exemplary BsAbs may bind to two different epitopes of the CD18 antigen or may bind both CD18 and CD11b. Such antibodies can be derived from full length antibodies or antibody fragments (e.g.  $F(ab')_2$  bispecific 30 antibodies).

Methods for making bispecific antibodies are known in the art. Traditional production of full length bispecific antibodies is based on the coexpression of two immunoglobulin heavy chain-light chain pairs, where the two chains have different specificities (Millstein *et al.*, *Nature*, 305:537-539 (1983)). Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture 35 of 10 different antibody molecules, of which only one has the correct bispecific structure. Purification of the correct molecule, which is usually done by affinity chromatography steps, is rather cumbersome, and the product yields are low. Similar procedures are disclosed in WO 93/08829, published 13 May 1993, and in Traunecker *et al.*, *EMBO J.*, 10:3655-3659 (1991).

According to a different and more preferred approach, antibody variable domains with the desired binding specificities (antibody-antigen combining sites) are fused to immunoglobulin constant domain sequences. The fusion preferably is with an immunoglobulin heavy chain constant domain, comprising at least part of the hinge, CH<sub>2</sub>, and CH<sub>3</sub> regions. It is preferred to have the first heavy-chain constant region (CH<sub>1</sub>) containing the site necessary for light chain binding, present in at least one of the fusions. DNAs encoding the immunoglobulin heavy chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are co-transfected into a suitable host organism. This provides for great flexibility in adjusting the mutual proportions of the three polypeptide fragments in embodiments when unequal ratios of the three polypeptide chains used in the construction provide the optimum yields. It is, however, possible to insert the coding sequences for two or all three polypeptide chains in one expression vector when the expression of at least two polypeptide chains in equal ratios results in high yields or when the ratios are of no particular significance.

In a preferred embodiment of this approach, the bispecific antibodies are composed of a hybrid immunoglobulin heavy chain with a first binding specificity in one arm, and a hybrid immunoglobulin heavy chain-light chain pair (providing a second binding specificity) in the other arm. It was found that this asymmetric structure facilitates the separation of the desired bispecific compound from unwanted immunoglobulin chain combinations, as the presence of an immunoglobulin light chain in only one half of the bispecific molecule provides for a facile way of separation. This approach is disclosed in WO 94/04690 published March 3, 1994. For further details of generating bispecific antibodies see, for example, Suresh *et al.*, *Methods in Enzymology*, 121:210 (1986). Using such techniques, a bispecific molecule which combines a thrombolytic agent such as t-PA and an anti-CD18 or anti-CD11b antibody can be prepared for use in the treatment of stroke as defined herein.

Bispecific antibodies include cross-linked or "heteroconjugate" antibodies. For example, one of the antibodies in the heteroconjugate can be coupled to avidin, the other to biotin. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells (US Patent No. 4,676,980), and for treatment of HIV infection (WO 91/00360, WO 92/200373, and EP 03089). Heteroconjugate antibodies may be made using any convenient cross-linking methods. Suitable cross-linking agents are well known in the art, and are disclosed in US Patent No. 4,676,980, along with a number of cross-linking techniques.

Techniques for generating bispecific antibodies from antibody fragments have also been described in the literature. The following techniques can also be used for the production of bivalent antibody fragments which are not necessarily bispecific. For example, Fab' fragments recovered from *E. coli* can be chemically coupled *in vitro* to form bivalent antibodies. See, Shalaby *et al.*, *J. Exp. Med.*, 175:217-225 (1992).

Various techniques for making and isolating bivalent antibody fragments directly from recombinant cell culture have also been described. For example, bivalent heterodimers have been produced using leucine zippers. Kostelny *et al.*, *J. Immunol.*, 148(5):1547-1553 (1992). The leucine zipper peptides from the Fos and Jun proteins were linked to the Fab' portions of two different antibodies by gene fusion. The antibody homodimers were reduced at the hinge region to form monomers and then re-oxidized to form the antibody heterodimers. The "diabody" technology described by Hollinger *et al.*, *Proc. Natl. Acad. Sci. USA*, 90:6444-6448 (1993) has provided an alternative mechanism for making bispecific/bivalent antibody fragments. The fragments comprise a heavy-chain variable domain ( $V_H$ ) connected to a light-chain variable domain ( $V_L$ ) by a linker which is too short to allow pairing between the two domains on the same chain. Accordingly, the  $V_H$  and  $V_L$  domains of one

fragment are forced to pair with the complementary  $V_L$  and  $V_H$  domains of another fragment, thereby forming two antigen-binding sites. Another strategy for making bispecific/bivalent antibody fragments by the use of single-chain Fv (sFv) dimers has also been reported. See Gruber *et al.*, *J. Immunol.*, 152:5368 (1994).

#### B. Long half-life antagonists

5 In certain embodiments of the invention, it is desirable to use CD18 or CD11b antagonists engineered to have an enhanced half-life in the serum of a mammal treated therewith. For example, this may be achieved by (i) incorporating a salvage receptor binding epitope of the Fc region of an IgG into the antagonist so as to increase its circulatory half-life, but without disrupting its biological activity or (ii) covalently binding a nonproteinaceous polymer to the antagonist. These exemplary techniques will be described briefly below:

10 (i) *Antagonist-salvage receptor binding epitope fusions.*

Incorporation of a salvage receptor binding epitope into the antagonist can take place by any means, such as by mutation of the appropriate region in the antagonist of interest to mimic the Fc region or by incorporating the epitope into a peptide tag that is then fused to the antagonist at either end or in the middle or by DNA or peptide synthesis.

15 A systematic method for preparing such an antagonist variant having an increased *in vivo* half-life comprises several steps. The first involves identifying the sequence and conformation of a salvage receptor binding epitope of an Fc region of an IgG molecule. Once this epitope is identified, the sequence of the antagonist of interest is modified to include the sequence and conformation of the identified binding epitope. After the sequence is mutated, the antagonist variant is tested to see if it has a longer *in vivo* half-life than that 20 of the original antagonist. If the antagonist variant does not have a longer *in vivo* half-life upon testing, its sequence is further altered to include the sequence and conformation of the identified binding epitope. The altered antagonist is tested for longer *in vivo* half-life, and this process is continued until a molecule is obtained that exhibits a longer *in vivo* half-life.

25 The salvage receptor binding epitope being thus incorporated into the antagonist of interest is any suitable such epitope as defined above, and its nature will depend, e.g., on the type of antagonist being modified. The transfer is made such that the antagonist of interest is still able to antagonize the biological activity of CD11b or CD18.

30 Where the antagonist of interest is an antibody, it contains an Ig domain or Ig-like domain and the salvage receptor binding epitope is placed so that it is located within this Ig domain or Ig-like domain. More preferably, the epitope constitutes a region wherein any one or more amino acid residues from one or two loops of the Fc domain are transferred to an analogous position of the Ig domain or Ig-like domain of the antibody. Even more preferably, three or more residues from one or two loops of the Fc domain are transferred. Still more preferred, the epitope is taken from the CH2 domain of the Fc region (e.g., of an IgG) and transferred to the CH1, 35 CH3, or  $V_H$  region, or more than one such region, of an Ig or to a Ig-like domain. Alternatively, the epitope is taken from the CH2 domain of the Fc region and transferred to the  $C_L$  region or  $V_L$  region, or both, of an Ig or to an Ig-like domain of the antagonist of interest.

For example, for purposes of discussing variants wherein the polypeptide of interest is an antibody, reference is made to Figs. 4A-B, which illustrates the relevant consensus primary structures of various Igs, i.e., human IgG<sub>1</sub> CH1 domain, human IgG<sub>2</sub> CH1 domain, human IgG<sub>3</sub> CH1 domain, human IgG<sub>4</sub> CH1 domain,

human  $\kappa C_L$  domain, and human  $\lambda C_L$  domain, as well as the specific sequence for Fabv1b, a preferred anti-CD18 Fab variant herein. Further, Figs. 4A-B indicates the residues of Fabv1b that are of interest and of most importance. In a preferred embodiment, the residues of importance are those with an asterisk in Figs. 4A-B, i.e., in one loop of Fabv1b, MIS with a T residue one amino acid C-terminal to MIS, and in another loop of Fabv1b, HQN with a D residue two amino acids C-terminal to HQN and a K residue one amino acid C-terminal to the D residue.

In one most preferred embodiment, the salvage receptor binding epitope comprises the sequence (5' to 3'): PKNSSMISNTP (SEQ ID NO: 8), and optionally further comprises a sequence selected from the group consisting of HQSLGTQ (SEQ ID NO: 14), HQNLSDGK (SEQ ID NO: 9), HQNISDGK (SEQ ID NO: 15), 10 or VISSH LGQ (SEQ ID NO: 16), particularly where the antagonist of interest is a Fab or F(ab')<sub>2</sub>.

(ii) *Antagonist-polymer conjugates.*

The nonproteinaceous polymer of choice for this purpose is ordinarily is a hydrophilic synthetic polymer, i.e., a polymer not otherwise found in nature. However, polymers which exist in nature and are produced by recombinant or *in vitro* methods are useful, as are polymers which are isolated from native sources. 15 Hydrophilic polyvinyl polymers fall within the scope of this invention, e.g. polyvinylalcohol and polyvinylpyrrolidone. Particularly useful are polyalkylene ethers such as polyethylene glycol (PEG); polyalkylenes such as polyoxyethylene, polyoxypropylene, and block copolymers of polyoxyethylene and polyoxypropylene (Pluronics); polymethacrylates; carboxomers; branched or unbranched polysaccharides which comprise the saccharide monomers D-mannose, D- and L-galactose, fucose, fructose, D-xylose, L-arabinose, D- 20 glucuronic acid, sialic acid, D-galacturonic acid, D-mannuronic acid (e.g. polymannuronic acid, or alginic acid), D-glucosamine, D-galactosamine, D-glucose and neuraminic acid including homopolysaccharides and heteropolysaccharides such as lactose, amylopectin, starch, hydroxyethyl starch, amylose, dextrane sulfate, dextran, dextrans, glycogen, or the polysaccharide subunit of acid mucopolysaccharides, e.g. hyaluronic acid; polymers of sugar alcohols such as polyisorbitol and polymannitol; heparin or heparon. The polymer prior to cross-linking need not be, but preferably is, water soluble, but the final conjugate must be water soluble. In addition, the polymer should not be highly immunogenic in the conjugate form, nor should it possess viscosity 25 that is incompatible with intravenous infusion or injection if it is intended to be administered by such routes.

Preferably the polymer contains only a single group which is reactive. This helps to avoid cross-linking of protein molecules. However, it is within the scope herein to optimize reaction conditions to reduce cross-linking, or to purify the reaction products through gel filtration or chromatographic sieves to recover substantially 30 homogenous derivatives.

The molecular weight of the polymer may desirably range from about 100 to 500,000, and preferably is from about 1,000 to 20,000. The molecular weight chosen will depend upon the nature of the polymer and the degree of substitution. In general, the greater the hydrophilicity of the polymer and the greater the degree 35 of substitution, the lower the molecular weight that can be employed. Optimal molecular weights will be determined by routine experimentation.

The polymer generally is covalently linked to the antagonist though a multifunctional crosslinking agent which reacts with the polymer and one or more amino acid or sugar residues of the antagonist to be linked.

However, it is within the scope of the invention to directly crosslink the polymer by reacting a derivatized polymer with the hybrid, or vice versa.

Covalent binding to amino groups is accomplished by known chemistries based upon cyanuric chloride, carbonyl diimidazole, aldehyde reactive groups (PEG alkoxide plus diethyl acetal of bromoacetaldehyde; PEG plus DMSO and acetic anhydride, or PEG chloride plus the phenoxide of 4-hydroxybenzaldehyde, succinimidyl active esters, activated dithiocarbonate PEG, 2,4,5-trichlorophenylchloroformate or P-nitrophenylchloroformate activated PEG). Carboxyl groups are derivatized by coupling PEG-amine using carbodiimide.

Polymers are conjugated to oligosaccharide groups by oxidation using chemicals, e.g. metaperiodate, or enzymes, e.g. glucose or galactose oxidase, (either of which produces the aldehyde derivative of the carbohydrate), followed by reaction with hydrazide or amino derivatized polymers, in the same fashion as is described by Heitzmann *et al.*, *Proc. Natl Acad. Sci. USA* 71:3537-41 (1974) or Bayer *et al.*, *Methods in Enzymology* 62:310 (1979), for the labeling of oligosaccharides with biotin or avidin. Further, other chemical or enzymatic methods which have been used heretofore to link oligosaccharides are particularly advantageous because, in general, there are fewer substitutions than amino acid sites for derivatization, and the oligosaccharide products thus will be more homogenous. The oligosaccharide substituents also are optionally modified by enzyme digestion to remove sugars, e.g. by neuraminidase digestion, prior to polymer derivatization.

The polymer will bear a group which is directly reactive with an amino acid side chain, or the N- or C-terminus of the antagonist linked, or which is reactive with the multifunctional cross-linking agent. In general, polymers bearing such reactive groups are known for the preparation of immobilized proteins. In order to use such chemistries here, one should employ a water soluble polymer otherwise derivatized in the same fashion as insoluble polymers heretofore employed for protein immobilization. Cyanogen bromide activation is a particularly useful procedure to employ in crosslinking polysaccharides.

"Water soluble" in reference to the starting polymer means that the polymer or its reactive intermediate used for conjugation is sufficiently water soluble to participate in a derivatization reaction. "Water soluble" in reference to the polymer conjugate means that the conjugate is soluble in physiological fluids such as blood.

The degree of substitution with such a polymer will vary depending upon the number of reactive sites on the antagonist, whether all or a fragment of the antagonist is used, whether the antagonist is a fusion with a heterologous protein (e.g. anti-CD18 antibody fused to a salvage receptor binding epitope), the molecular weight, hydrophilicity and other characteristics of the polymer, and the particular antagonist derivatization sites chosen. In general, the conjugate contains about from 1 to 10 polymer molecules, while any heterologous sequence may be substituted with an essentially unlimited number of polymer molecules so long as the desired activity is not significantly adversely affected. The optimal degree of cross-linking is easily determined by an experimental matrix in which the time, temperature and other reaction conditions are varied to change the degree of substitution, after which the ability of the conjugates to function in the desired fashion is determined.

The polymer, e.g. PEG, is cross-linked by a wide variety of methods known *per se* for the covalent modification of proteins with nonproteinaceous polymers such as PEG.

The long half-life conjugates of this invention are separated from the unreacted starting materials by gel filtration. Heterologous species of the conjugates are purified from one another in the same fashion. The polymer also may be water-insoluble, as a hydrophilic gel.

### C. Pharmaceutical Formulations

Therapeutic formulations of the CD11b or CD18 antagonist are prepared for storage by mixing the antagonist having the desired degree of purity with optional physiologically acceptable carriers, excipients or stabilizers (*Remington's Pharmaceutical Sciences* 16th edition, Osol, A. Ed. (1980)), in the form of lyophilized formulations or aqueous solutions. Acceptable carriers, excipients or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate and other organic acids; antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin or immunoglobulins; amino acids such as glycine, glutamine, asparagine, histidine, arginine or lysine; monosaccharides, disaccharides and other carbohydrates including glucose, mannose, trehalose or dextrans; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and/or nonionic surfactants such as Tween, Pluronics or PEG.

The active ingredients may also be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacrylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules) or in macroemulsions. Such techniques are disclosed in *Remington's Pharmaceutical Sciences* 16th edition, Osol, A. Ed. (1980).

The formulations to be used for *in vivo* administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes, prior to or following lyophilization and reconstitution.

Sustained-release preparations may be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the CD18 or CD11b antagonist, which matrices are in the form of shaped articles, e.g. films, or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)), polylactides (U.S. Pat. No. 3,773,919), copolymers of L-glutamic acid and  $\gamma$  ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as the Lupron Depot<sup>TM</sup> (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid. While polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods. When encapsulated antibodies remain in the body for a long time, they may denature or aggregate as a result of exposure to moisture at 37°C, resulting in a loss of biological activity and possible changes in immunogenicity. Rational strategies can be devised for stabilization depending on the mechanism involved. For example, if the aggregation mechanism is discovered to be intermolecular S-S bond formation through thio-disulfide interchange, stabilization may be achieved by modifying sulphydryl residues, lyophilizing from acidic solutions, controlling moisture content, using appropriate additives, and developing specific polymer matrix compositions.

Sustained-release CD18 or CD11b antagonist compositions also include liposomally entrapped antagonists. Liposomes containing the CD18 or CD11b antagonist are prepared by methods known in the art, such as described in Epstein *et al.*, *Proc. Natl. Acad. Sci. USA*, 82:3688 (1985); Hwang *et al.*, *Proc. Natl. Acad. Sci. USA*, 77:4030 (1980); and U.S. Pat. Nos. 4,485,045 and 4,544,545. Ordinarily, the liposomes are the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol.% cholesterol.

the selected proportion being adjusted for the optimal CD18 or CD11b antagonist therapy. Liposomes with enhanced circulation time are disclosed in U.S. Patent No. 5,013,556.

#### D. Modes for Administration

The CD18 or CD11b antagonists of the invention are administered to a mammal, preferably a human, 5 in accord with known methods, such as intravenous administration as a bolus or by continuous infusion over a period of time, by intramuscular, intraperitoneal, intracerebrospinal, subcutaneous, intra-articular, intrasynovial, intrathecal, oral, topical, or inhalation routes. Intravenous administration of the antagonist is preferred.

The appropriate dosage of CD18 or CD11b antagonist will depend on the nature of the stroke to be treated, the severity and course of the stroke, whether the antagonist is administered for preventive or therapeutic 10 purposes, previous therapy, the patient's clinical history and response to the CD18 or CD11b antagonist, and the discretion of the attending physician. The CD18 or CD11b antagonist is suitably administered to the patient at one time or over a series of treatments and may be administered to the patient at any time from diagnosis onwards. For example, the antagonist may be administered at a time between about 15, 30 or 45 minutes to about 15 5 hours, 12 hours or 24 hours from the onset of stroke. In preferred embodiments, the initial dose is followed by at least one subsequent dose (e.g., from 5 to 24 hours after the initial dose). In certain situations, CD11b antagonist and CD18 antagonist are co-administered to the mammal.

Where the antagonist is an antibody, from about 100 $\mu$ g/kg to about 20mg/kg, and preferably from about 500 $\mu$ g/kg to about 5 mg/kg, and most preferably from about 1mg/kg to about 3mg/kg of the anti-CD18 or anti-CD11b antibody is an initial candidate dosage for administration to the patient, whether, for example, by one or 20 more separate administrations, or by continuous infusion. However, other dosage regimens may be useful. The progress of this therapy is easily monitored by conventional techniques and assays elaborated herein.

#### E. Kits and Articles of Manufacture

In another embodiment of the invention, there are provided articles of manufacture and kits containing materials useful for improving clinical outcome in stroke by increasing cerebral blood flow and/or reducing 25 infarct size. The article of manufacture comprises a container with a label. Suitable containers include, for example, bottles, vials, and test tubes. The containers may be formed from a variety of materials such as glass or plastic. The container holds a composition which is effective for treating stroke as defined herein and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). The active agent in the composition is a CD11b or CD18 30 antagonist. The label on the container indicates that the composition is used for treating stroke as described above, and may also indicate directions for *in vivo* use, such as those described above.

The kit of the invention comprises the container described above and a second container comprising a pharmaceutically-acceptable buffer, such as phosphate-buffered saline, Ringer's solution and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, 35 diluents, filters, needles, syringes, and package inserts with instructions for use.

The following examples are offered by way of illustration and not by way of limitation. The disclosures of all citations in the specification are expressly incorporated herein by reference.

#### EXAMPLE

This study investigated the effect of anti-CD18 antibody (MHM23) and t-PA in a rabbit model of 40 thromboembolic stroke. In this model, a single blood clot is introduced into the middle cerebral and posterior

communicating arteries (which are "main cerebral arteries"). The arterial obstruction (i.e., the clot) remains in place throughout the experiment (unless it is enzymatically removed by t-PA). The following rabbit model is thought to correlate well with the physiological progression of thromboembolic stroke in humans.

#### Materials and Methods

The rabbit model of thromboembolic stroke used in the current study has been previously described in detail (Bednar *et al.*, *Neurol. Res.*, 16:129-132 (1994); Gross *et al.*, *Stroke*, 24:558-562 (1993); Kohut *et al.*, *Stroke*, 23:93-97 (1992); Wilson *et al.*, *Neurosurgery*, 31:929-934 (1992)). See, also, Gross *et al.*, *Neurosurgery*, 36(6):1172-1177 (1995).

Briefly, New Zealand white rabbits (Charles River, CA) (both males and females; 3.0-3.5kg) were anesthetized with the solution of ketamine (50mg/kg; Aveco Co., Fort Dodge, IA), acepromazine (20 mg, Aveco Co.), and xylazine (5 mg/kg; Mobay Corp., Shawnee, KS), a solution that was subsequently used to maintain sufficient anesthesia for painless surgery (as determined by responses to various physiological and autonomic stimuli, including mean arterial pressure and response to a paw being pinched). After an incision was made in the right femoral triangle to expose the femoral vein and artery, the femoral artery was cannulated with a PE-90 catheter (BD Co., Parsippany, NJ), to which was attached a platinum-iridium electrode. This catheter-electrode permitted the continuous measuring of mean arterial pressure and blood sampling for measurement of arterial blood gases (ABG) (pH, PCO<sub>2</sub>, PO<sub>2</sub>), hematocrit, and glucose and for determination of hydrogen washout to assess the rCBF by the hydrogen clearance technique (Young, *Stroke*, 11:552-564 (1980)). After the femoral vein was cannulated with PE-90 tubing for drug infusions, a midline scalp incision was made to expose the calvarium. Bilateral craniectomies were performed and the following were placed: 30-gauge platinum-iridium electrodes to monitor the regional cerebral blood flow (rCBF); a fiberoptic, epidural intracranial pressure (ICP) monitor (Princeton Medical Corp., Hudson, NH); and a temperature sensor (Yellow Springs Instruments, Yellow Springs, OH) to measure brain temperature. All cranial instrumentation was carefully fixed in place with fast-setting epoxy. Through a midline neck incision, the animal was tracheostomized and mechanically ventilated. Both depth and rate of ventilation were modified as needed to maintain ABGs within physiological range.

Throughout the experiment, the brain and core temperatures, mean arterial pressure, and ICP were continuously measured. Additionally, the following parameters were measured before embolization (baseline), at the time of embolization, and hourly after embolization: the rCBF, hematocrit, glucose, and ABG. The mean arterial pressures were kept between 50 and 60 mm Hg throughout the experiment. Fluids (Ringer's lactate or packed cells) were given intravenously as needed (approximately 2-4 ml/kg/h) to maintain euvolemia. Core and brain temperatures were maintained within 1°C of baseline by using heating blankets and heating lamps.

The autologous clot was prepared by mixing the whole blood (1 ml) with 50 mg of tin granules. The clot was introduced into the PE-90 tubing pretreated with thrombin and was allowed to mature at room temperature.

After tracheostomy, the region of the bifurcation of the common carotid artery was identified, followed by 30 to 60 minutes of equilibration, during which baseline values were obtained. All surgery was completed within 2 hours. Once all the baseline values were obtained, the proximal internal carotid artery and the distal common carotid artery were transiently isolated from the circulation. An arteriotomy was then performed, and the autologous clot embolus was delivered to the anterior circulation of the brain via a catheter advanced into

the proximal internal carotid artery. Once embolized, both the proximal internal carotid artery and distal common carotid artery were again isolated from the circulation and an arteriography was performed by using 10-0 interrupted nylon sutures. A Philip's dental x-ray machine was used to obtain a submental-vertex radiograph that verified placement of the tin-tagged clot. Embolized clots were noted within the middle cerebral and posterior communicating arteries.

t-PA or a saline solution (0.9% saline) was administered intravenously by continuous infusion from hours 3-5 after the embolization at a total dose of 6.3 mg/kg. MHM23 (2 mg/kg) was administered by bolus dosage 1 hour after embolization. In each instance, the experiment continued for 7 hours after embolization. Submental-vertex radiographs were obtained after embolization and at the end of the experiment. Immediately 10 after the embolization, the rCBF was measured again; the experiment was continued if the rCBF was  $\leq 15 \text{ mL}/100 \text{ g}/\text{min}$  in any of the three electrodes in the embolized hemisphere (Jones *et al.*, *J. Neurosurg.*, 54:773-782 (1981)).

At the end of the experiment, the animals were killed with an overdose of sodium pentobarbital (150 mg/kg), a procedure recognized as acceptable and painless, according to the euthanasia guidelines of the 15 American Veterinary Medical Association. Bilateral thoracotomies were performed in accordance with procedures outlined by the University of Vermont Institutional Animal Care and Utilization Committee. The brain was harvested rapidly and examined grossly for the presence and position of residual clot. The brain was cut into 2-mm slices in a bread-loaf fashion and incubated in triphenyltetrazolium chloride dye to define the size 20 of the brain infarct (Bose *et al.*, *Stroke*, 19:28-37 (1988)). This method has been shown to be an acceptable means of determining the size of a brain infarct in our rabbit model and correlates well with hematoxylin and eosin staining (Bednar *et al.*, *Neurol. Res.*, 16:129-132 (1994)). Each brain slice was carefully traced onto clear acetate sheets for later planimetric determination of the infarct size, for which an IBM image analyzer was used. The infarct size was determined according to the modification described by Lin *et al.*, *Stroke*, 24:117-121 (1993). In this method, the region of the infarct is determined by subtracting the volume of the noninfarcted part of the 25 embolized hemisphere from the entire volume of the nonembolized hemisphere. This modification takes into account that the volume of a brain infarct may be overestimated because of associated swelling.

The analysis of variance for repeated measures was used to analyze the hematocrit, glucose, ABG, rCBF, and ICP in the control and treated groups. If significance was noted, the values of these variables immediately before the t-PA and/or MHM23 administration were then compared by the Student's *t* test. When 30 necessary, the analysis of covariance was used to compare the control and treated groups. After a significant treatment-by-time interaction, individual contrasts were used to compare the treatment means at each time point; that is, if a significant treatment-by-time interaction was noted, the treatment effects were examined at each time point. The infarct size and specific gravities of the brain were compared (treated versus control) by the Student's *t* test. All the results were two-sided and were evaluated by using  $\alpha = 0.05$ .

35

## Results

The results of the above experiment are depicted in Figs. 1-3. As shown in Figs. 1 and 2, administration of anti-CD18 antibody alone, lead to a significant increase in cerebral blood flow as well as a significant reduction in infarct size relative to control. Fig. 3 shows that anti-CD18 antibody alone, t-PA alone, or a combination of these two agents tend to reduce intracranial pressure (ICP) at 6-7 hours. Furthermore, the

experiments show that anti-CD18 antibody is comparable with t-PA and improves the outcome of t-PA when given at 3-5 hours after installation of the clot into the cerebral circulation.

The increase in cerebral blood flow and the reduction in infarct size observed in the above experiments are thought to be predictive of an improvement in clinical outcome as measured by a standard stroke scale.

- 5 Accordingly, this application provides a method for improving clinical outcome in patients having suffered stroke as defined herein.

The model described in this example differs from that previously described in Bednar *et al.*, Stroke 23(1):152 (1992) in that the animals in the study were not subjected to extraneous systemic hypotension (by reducing the mean arterial pressure in the animal to 30 mmHg by controlled exsanguination). Also, the anti-  
10 CD18 antibody was given more than 30 minutes after the thromboembolic event and the dose was different.

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

(i) APPLICANT: Genentech, Inc.  
University of Vermont and State Agricultural College

5 (ii) TITLE OF INVENTION: ANTI-CD18 ANTIBODIES IN STROKE

(iii) NUMBER OF SEQUENCES: 16

## (iv) CORRESPONDENCE ADDRESS:

- (A) ADDRESSEE: Genentech, Inc.  
(B) STREET: 460 Point San Bruno Blvd  
10 (C) CITY: South San Francisco  
(D) STATE: California  
(E) COUNTRY: USA  
(F) ZIP: 94080

## (v) COMPUTER READABLE FORM:

- 15 (A) MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk  
(B) COMPUTER: IBM PC compatible  
(C) OPERATING SYSTEM: PC-DOS/MS-DOS  
(D) SOFTWARE: WinPatin (Genentech)

## 20 (vi) CURRENT APPLICATION DATA:

- (A) APPLICATION NUMBER:  
(B) FILING DATE:  
(C) CLASSIFICATION:

## (viii) ATTORNEY/AGENT INFORMATION:

- 25 (A) NAME: Lee, Wendy M.  
(B) REGISTRATION NUMBER: 40,378  
(C) REFERENCE/DOCKET NUMBER: P0987PCT

## (ix) TELECOMMUNICATION INFORMATION:

- 30 (A) TELEPHONE: 415/225-1994  
(B) TELEFAX: 415/952-9881  
(C) TELEX: 910/371-7168

## (2) INFORMATION FOR SEQ ID NO:1:

## (i) SEQUENCE CHARACTERISTICS:

- 35 (A) LENGTH: 98 amino acids  
(B) TYPE: Amino Acid  
(D) TOPOLOGY: Linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser  
1 5 10 15

40 Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys  
20 25 30

Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala  
35 40 45

Leu	Thr	Ser	Gly	Val	His	Thr	Phe	Pro	Ala	Val	Leu	Gln	Ser	Ser	
				50					55				60		
Gly	Leu	Tyr	Ser	Leu	Ser	Ser	Val	Val	Thr	Val	Pro	Ser	Ser	Ser	
				65				70			75				
5	Leu	Gly	Thr	Gln	Thr	Tyr	Ile	Cys	Asn	Val	Asn	His	Lys	Pro	Ser
				80					85			90			
	Asn	Thr	Lys	Val	Asp	Lys	Arg	Val							
				95				98							

## (2) INFORMATION FOR SEQ ID NO:2:

- 10 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 98 amino acids  
 (B) TYPE: Amino Acid  
 (D) TOPOLOGY: Linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

15	Ala	Ser	Thr	Lys	Gly	Pro	Ser	Val	Phe	Pro	Leu	Ala	Pro	Cys	Ser
	1			5					10			15			
	Arg	Ser	Thr	Ser	Glu	Ser	Thr	Ala	Ala	Leu	Gly	Cys	Leu	Val	Lys
				20					25			30			
20	Asp	Tyr	Phe	Pro	Glu	Pro	Val	Thr	Val	Ser	Trp	Asn	Ser	Gly	Ala
				35					40			45			
	Leu	Thr	Ser	Gly	Val	His	Thr	Phe	Pro	Ala	Val	Leu	Gln	Ser	Ser
				50					55			60			
	Gly	Leu	Tyr	Ser	Leu	Ser	Ser	Val	Val	Thr	Val	Pro	Ser	Ser	Asn
				65					70			75			
25	Phe	Gly	Thr	Gln	Thr	Tyr	Thr	Cys	Asn	Val	Asp	His	Lys	Pro	Ser
				80					85			90			
	Asn	Thr	Lys	Val	Asp	Lys	Thr	Val							
				95				98							

## (2) INFORMATION FOR SEQ ID NO:3:

- 30 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 98 amino acids  
 (B) TYPE: Amino Acid  
 (D) TOPOLOGY: Linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

35	Ala	Ser	Thr	Lys	Gly	Pro	Ser	Val	Phe	Pro	Leu	Ala	Pro	Cys	Ser
	1			5					10			15			
	Arg	Ser	Thr	Ser	Gly	Gly	Thr	Ala	Ala	Leu	Gly	Cys	Leu	Val	Lys
				20					25			30			
	Asp	Tyr	Phe	Pro	Glu	Pro	Val	Thr	Val	Ser	Trp	Asn	Ser	Gly	Ala

35	40	45
Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser		
50	55	60
Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser		
65	70	75
Leu Gly Thr Gln Thr Tyr Thr Cys Asn Val Asn His Lys Pro Ser		
80	85	90
Asn Thr Lys Val Asp Lys Arg Val		
95	98	

## 10 (2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 98 amino acids
  - (B) TYPE: Amino Acid
  - (D) TOPOLOGY: Linear

## 15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser		
1	5	10
Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys		
20	25	30
Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala		
35	40	45
Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser		
50	55	60
Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser		
65	70	75
Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser		
80	85	90
Asn Thr Lys Val Asp Lys Arg Val		
95	98	

## 20 (2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 107 amino acids
  - (B) TYPE: Amino Acid
  - (D) TOPOLOGY: Linear

## 25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp		
1	5	10
Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn		
20	25	30

	Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn		
	35	40	45
	Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp		
	50	55	60
5	Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser		
	65	70	75
	Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr		
	80	85	90
10	His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly		
	95	100	105
	Glu Cys		
	107		

## (2) INFORMATION FOR SEQ ID NO:6:

15	(i) SEQUENCE CHARACTERISTICS:		
	(A) LENGTH: 105 amino acids		
	(B) TYPE: Amino Acid		
	(D) TOPOLOGY: Linear		
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:		
20	Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser		
	1                   5                   10                   15		
	Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser		
	20                   25                   30		
	Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser		
	35                   40                   45		
25	Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln		
	50                   55                   60		
	Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro		
	65                   70                   75		
30	Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His		
	80                   85                   90		
	Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser		
	95                   100                  105		

## (2) INFORMATION FOR SEQ ID NO:7:

35	(i) SEQUENCE CHARACTERISTICS:		
	(A) LENGTH: 100 amino acids		
	(B) TYPE: Amino Acid		
	(D) TOPOLOGY: Linear		
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:		
	Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Pro		

1	S	10	15
Lys Asn Ser Ser Met Ile Ser Asn Thr Pro Ala Leu Gly Cys Leu			
	20	25	30
Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser			
5	35	40	45
Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln			
	50	55	60
Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro His			
	65	70	75
10 Gln Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys			
	80	85	90
Pro Ser Asn Thr Lys Val Asp Lys Arg Val			
	95	100	

## (2) INFORMATION FOR SEQ ID NO:8:

- 15 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 11 amino acids  
 (B) TYPE: Amino Acid  
 (D) TOPOLOGY: Linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

20	Pro Lys Asn Ser Ser Met Ile Ser Asn Thr Pro		
	1	5	10 11

## (2) INFORMATION FOR SEQ ID NO:9:

- 25 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 8 amino acids  
 (B) TYPE: Amino Acid  
 (D) TOPOLOGY: Linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

His Gln Asn Leu Ser Asp Gly Lys		
1	5	8

## 30 (2) INFORMATION FOR SEQ ID NO:10:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 232 amino acids  
 (B) TYPE: Amino Acid  
 (D) TOPOLOGY: Linear

## 35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly			
1	5	10	15

Gly Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Tyr Thr Phe Thr		
20	25	30

Glu Tyr Thr Met His Trp Met Arg Gln Ala Pro Gly Lys Gly Leu  
                  35                        40                        45

Glu Trp Val Ala Gly Ile Asn Pro Lys Asn Gly Gly Thr Ser His  
                  50                        55                        60

5 Asn Gln Arg Phe Met Asp Arg Phe Thr Ile Ser Val Asp Lys Ser  
       65                        70                        75

Thr Ser Thr Ala Tyr Met Gln Met Asn Ser Leu Arg Ala Glu Asp  
       80                        85                        90

10 Thr Ala Val Tyr Tyr Cys Ala Arg Trp Arg Gly Leu Asn Tyr Gly  
       95                        100                        105

Phe Asp Val Arg Tyr Phe Asp Val Trp Gly Gln Gly Thr Leu Val  
      110                        115                        120

Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu  
      125                        130                        135

15 Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly  
      140                        145                        150

Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp  
      155                        160                        165

20 Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val  
      170                        175                        180

Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val  
      185                        190                        195

Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn  
      200                        205                        210

25 His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys  
      215                        220                        225

Ser Cys Asp Lys Thr His Thr  
      230                        232

## (2) INFORMATION FOR SEQ ID NO:11:

## 30 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 214 amino acids
- (B) TYPE: Amino Acid
- (D) TOPOLOGY: Linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

35 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val  
      1                        5                        10                        15

Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Asn  
      20                        25                        30

Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys

	35	40	45
	Leu Leu Ile Tyr Tyr Thr Ser Thr Leu His Ser Gly Val Pro Ser		
	50	55	60
	Arg Phe Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile		
	65	70	75
	Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln		
	80	85	90
	Gly Asn Thr Leu Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu		
	95	100	105
10	Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro		
	110	115	120
	Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu		
	125	130	135
15	Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val		
	140	145	150
	Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu		
	155	160	165
	Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr		
	170	175	180
20	Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu		
	185	190	195
	Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn		
	200	205	210
25	Arg Gly Glu Cys		
	214		

## (2) INFORMATION FOR SEQ ID NO:12:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 450 amino acids
  - (B) TYPE: Amino Acid
  - 30 (D) TOPOLOGY: Linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

	Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly			
	1	5	10	15
	Gly Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Tyr Thr Phe Thr			
35	20	25	30	
	Glu Tyr Thr Met His Trp Met Arg Gln Ala Pro Gly Lys Gly Leu			
	35	40	45	
	Glu Trp Val Ala Gly Ile Asn Pro Lys Asn Gly Gly Thr Ser His			
	50	55	60	

	Asn Gln Arg Phe Met Asp Arg Phe Thr Ile Ser Val Asp Lys Ser		
	65	70	75
	Thr Ser Thr Ala Tyr Met Gln Met Asn Ser Leu Arg Ala Glu Asp		
	80	85	90
5	Thr Ala Val Tyr Tyr Cys Ala Arg Trp Arg Gly Leu Asn Tyr Gly		
	95	100	105
	Phe Asp Val Arg Tyr Phe Asp Val Trp Gly Gln Gly Thr Leu Val		
	110	115	120
10	Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu		
	125	130	135
	Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly		
	140	145	150
	Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp		
	155	160	165
15	Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val		
	170	175	180
	Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val		
	185	190	195
20	Thr Ser Ser Asn Phe Gly Thr Gln Thr Tyr Thr Cys Asn Val Asp		
	200	205	210
	His Lys Pro Ser Asn Thr Lys Val Asp Lys Thr Val Glu Arg Lys		
	215	220	225
	Cys Cys Val Glu Cys Pro Pro Cys Pro Ala Pro Pro Val Ala Gly		
	230	235	240
25	Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met		
	245	250	255
	Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser		
	260	265	270
30	His Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Met		
	275	280	285
	Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn		
	290	295	300
	Ser Thr Phe Arg Val Val Ser Val Leu Thr Val Val His Gln Asp		
	305	310	315
35	Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly		
	320	325	330
	Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Thr Lys Gly Gln		
	335	340	345
	Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu		

	350	355	360
	Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe		
	365	370	375
5	Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro		
	380	385	390
	Glu Asn Asn Tyr Lys Thr Thr Pro Pro Met Leu Asp Ser Asp Gly		
	395	400	405
	Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp		
	410	415	420
10	Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu		
	425	430	435
	His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys		
	440	445	450

## (2) INFORMATION FOR SEQ ID NO:13:

- 15 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 214 amino acids  
 (B) TYPE: Amino Acid  
 (D) TOPOLOGY: Linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

20	Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val		
	1	5	10
	15		
	Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Asn		
	20	25	30
25	Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys		
	35	40	45
	Leu Leu Ile Tyr Tyr Ser Thr Leu His Ser Gly Val Pro Ser		
	50	55	60
	Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile		
	65	70	75
30	Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln		
	80	85	90
	Gly Asn Thr Leu Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu		
	95	100	105
35	Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro		
	110	115	120
	Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu		
	125	130	135
	Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val		
	140	145	150

Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu  
155 160 165  
Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr  
170 175 180  
5 Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu  
185 190 195  
Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn  
200 205 210  
10 Arg Gly Glu Cys  
214

## (2) INFORMATION FOR SEQ ID NO:14:

- 15 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 7 amino acids  
(B) TYPE: Amino Acid  
(D) TOPOLOGY: Linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

His Gln Ser Leu Gly Thr Gln  
1 5 7

## (2) INFORMATION FOR SEQ ID NO:15:

- 20 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 8 amino acids  
(B) TYPE: Amino Acid  
(D) TOPOLOGY: Linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

25 His Gln Asn Ile Ser Asp Gly Lys  
1 5 8

## (2) INFORMATION FOR SEQ ID NO:16:

- 30 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 8 amino acids  
(B) TYPE: Amino Acid  
(D) TOPOLOGY: Linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

Val Ile Ser Ser His Leu Gly Gln  
1 5 8

## WHAT IS CLAIMED IS:

1. A method for treating focal ischemic stroke caused by obstruction of a main cerebral artery in a mammal comprising administering an amount of anti-CD18 antibody to the mammal which is effective for increasing cerebral blood flow or reducing infarct size, in the absence of removal of the arterial obstruction.
- 5 2. The method of claim 1 which increases cerebral blood flow and reduces infarct size in the mammal.
3. The method of claim 1 wherein the anti-CD18 antibody is an antibody fragment.
4. The method of claim 3 wherein the anti-CD18 antibody fragment is a F(ab')<sub>2</sub>.
5. The method of claim 1 wherein the anti-CD18 antibody is humanized.
- 10 6. The method of claim 1 wherein the anti-CD18 antibody is administered to the mammal by bolus dosage.
7. The method of claim 1 wherein the anti-CD18 antibody is administered intravenously.
8. The method of claim 1 wherein the anti-CD18 antibody is administered via continuous infusion.
- 15 9. The method of claim 1 wherein the anti-CD18 antibody is administered to the mammal at a time between about 15 minutes to about 20 hours from the onset of focal ischemic stroke.
10. The method of claim 9 wherein the anti-CD18 antibody is administered to the mammal at a time between about 45 mins to about 5 hours from the onset of focal ischemic stroke.
11. The method of claim 1 wherein the anti-CD18 antibody is humanized H52 antibody.
- 20 12. The method of claim 11 wherein the H52 antibody is a F(ab')<sub>2</sub>.
13. The method of claim 3 wherein the anti-CD18 antibody fragment is fused to a salvage receptor binding epitope.
14. The method of claim 1 wherein the mammal is a human.
15. An article of manufacture, comprising:  
25 a container;  
a label on said container; and  
a composition comprising an active agent contained within said container; wherein the composition is effective for increasing cerebral blood flow or reducing infarct size in focal ischemic stroke caused by obstruction of a main cerebral artery, the label on said container indicates that the composition can be used for treating stroke and the active agent in said composition is an antagonist anti-CD18 antibody.
- 30 16. The article of manufacture of claim 15 further comprising instructions for administering the anti-CD18 antibody to a mammal to increase cerebral blood flow or reduce infarct size in focal ischemic stroke.

17. A kit comprising:

- a first container, a label on said container, and a composition comprising an active agent contained within said container; wherein the composition is effective for increasing cerebral blood flow or reducing infarct size in focal ischemic stroke caused by obstruction of a main cerebral artery, the label on said container indicates  
5 that the composition can be used for treating stroke, and the active agent in said composition is an antagonist anti-CD18 antibody;
- a second container comprising a pharmaceutically-acceptable buffer; and  
instructions for using the anti-CD18 antibody to increase cerebral blood flow or reduce infarct size in focal ischemic stroke.

10




Figure 1




Figure 2




Figure 3

hIgG<sub>1</sub> Sequence of human IgG1 CH1 domain  
 hIgG<sub>2</sub> Sequence of human IgG2 CH1 domain  
 hIgG<sub>3</sub> Sequence of human IgG3 CH1 domain  
 hIgG<sub>4</sub> Sequence of human IgG4 CH1 domain  
 humκ Sequence of human kappa CL domain  
 humλ Sequence of human lambda CL domain

---

	114	128	139
hIgG <sub>1</sub>	A S T K G P S V F P L A P S S K S T S G G T A A L		
hIgG <sub>2</sub>	A S T K G P S V F P L A P C S R S T S E S T A A L		
hIgG <sub>3</sub>	A S T K G P S V F P L A P C S R S T S G G T A A L		
hIgG <sub>4</sub>	A S T K G P S V F P L A P C S R S T S E S T A A L		
	108	122	131
humκ	R T V A A P S V F I F P P S D E Q L K S G T A S V		
humλ	Q P K A A P S V T L F P P S S E E L Q A N K A T L		
	-----		
Fabv1b of interest	A S T K G P S V F P L A P S P K N S S M I S N T P A L		
most important		***	

---

hIgG <sub>1</sub>	G C L V K D Y F P E P V T V S W N S G A L T S	
hIgG <sub>2</sub>	G C L V K D Y F P E P V T V S W N S G A L T S	
hIgG <sub>3</sub>	G C L V K D Y F P E P V T V S W N S G A L T S	
hIgG <sub>4</sub>	G C L V K D Y F P E P V T V S W N S G A L T S	
humκ	V C L L N N F Y P R E A K V Q W K V D N A L Q	
humλ	V C L I S D F Y P G A V T V A W K A D S S P V	
	-----	
Fabv1b	G C L V K D Y F P E P V T V S W N S G A L T S	
hIgG <sub>1</sub>	G V H T F P A V L Q S S G - - - L Y S L S S V	
hIgG <sub>2</sub>	G V H T F P A V L Q S S G - - - L Y S L S S V	

---

hIgG <sub>1</sub>	G V H T F P A V L Q S S G - - -	L Y S L S S V
hIgG <sub>2</sub>	G V H T F P A V L Q S S G - - -	L Y S L S S V
humκ	S G N S Q E S V T E Q D S K D S T Y S L S S T	
humλ	K A G V E T T T P S K Q S N N - K Y A A S S Y	
<hr/>		
Fabv1b	G V H T F P A V L Q S S G - - -	L Y S L S S V
193                  200 203		
hIgG <sub>1</sub>	V T V P S S S L G T - Q T Y I C N V N H K P S	
hIgG <sub>2</sub>	V T V P S S S N F G T - Q T Y T C N V D H K P S	
hIgG <sub>3</sub>	V T V P S S S L G T - Q T Y T C N V N H K P S	
hIgG <sub>4</sub>	V T V P S S S L G T - K T Y T C N V D H K P S	
	181                  190	
humκ	L T L S K A D Y E K H K V Y A C E V T H Q G L	
humλ	L S L T P E Q W K S H R S Y S C Q V T H E G S	
<hr/>		
Fabv1b	V T V P H Q S L G T - Q T Y I C N V N H K P S	
of interest	H Q N L S D G K	
<hr/>		
most important	* * *          *	*
hIgG <sub>1</sub>	N T K V D K R V - - -	
hIgG <sub>2</sub>	N T K V D K T V - - -	
hIgG <sub>3</sub>	N T K V D K R V - - -	
hIgG <sub>4</sub>	N T K V D K R V - - -	
humκ	S S P V T K S F N R G E C	
humλ	T V E K T V A P T E C S	
<hr/>		
Fabv1b	N T K V D K R V - - -	

5 / 5

Figure 4B




PCT

**WORLD INTELLECTUAL PROPERTY ORGANIZATION**  
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : <b>A61K 39/395, A61J 1/00</b>		<b>A3</b>	(11) International Publication Number: <b>WO 97/26912</b>
			(43) International Publication Date: <b>31 July 1997 (31.07.97)</b>
(21) International Application Number: <b>PCT/US97/00492</b>		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: <b>11 January 1997 (11.01.97)</b>			
(30) Priority Data: 08/589,982                    23 January 1996 (23.01.96)                    US			
(71) Applicants: GENENTECH, INC. [US/US]; 460 Point San Bruno Boulevard, South San Francisco, CA 94080-4990 (US). UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE [US/US]; 85 South Prospect Street, Burlington, VT 05405-0160 (US).		Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(72) Inventors: BEDNAR, Martin, M.; 33 Bartlett Bay Road, South Burlington, VT 05403 (US). GROSS, Cordell, E.; 1001 Dorset Street, South Burlington, VT 05403 (US). THOMAS, G., Roger; 812 Park Avenue, Burlingame, CA 94010 (US).		(88) Date of publication of the international search report: <b>9 October 1997 (09.10.97)</b>	
(74) Agents: HASAK, Janet, E. et al.; Genentech, Inc., 460 Point San Bruno Boulevard, South San Francisco, CA 94080-4990 (US).			

(54) Title: ANTI-CD18 ANTIBODIES FOR USE AGAINST STROKE



**(57) Abstract**

A method for improving clinical outcome in focal ischemic stroke in a mammal by increasing cerebral blood flow and/or reducing infarct size is described which involves administering an effective amount of an anti-CD18 antibody to the mammal, in the absence of removal of the arterial obstruction.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

# INTERNATIONAL SEARCH REPORT

Intern. Appl. No.

PCT/US 97/00492

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 6 A61K39/395 A61J1/00

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	AMERICAN JOURNAL OF PATHOLOGY, vol. 148, no. 1, January 1996, HAGERSTOWN, MD, USA, pages 241-248, XP002036510 J. GARCIA ET AL.: "Effects of CD11b/18 monoclonal antibody on rats with permanent middle cerebral artery occlusion." see abstract	1-17
Y	AMERICAN JOURNAL OF PHYSIOLOGY, vol. 270, no. 1 part 2, 1996, WASHINGTON, DC, USA, pages H53-H64, XP002036511 R. PEREZ ET AL.: "Factors modifying protective effect of anti-CD18 antibodies on myocardial reperfusion injury in dogs." see abstract	1-17

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- \*'A' document defining the general state of the art which is not considered to be of particular relevance
- \*'E' earlier document but published on or after the international filing date
- \*'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*'O' document referring to an oral disclosure, use, exhibition or other means
- \*'P' document published prior to the international filing date but later than the priority date claimed

\*'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

\*'&' document member of the same patent family

1

Date of the actual completion of the international search

31 July 1997

Date of mailing of the international search report

26.08.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patendaan 2  
NL - 2280 HV Rijswijk  
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+ 31-70) 340-3016

Authorized officer

Nooij, F

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 97/00492

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 25, no. 3, 1 March 1995, NEW YORK, NY, USA, pages 781-788, XP002036512 T. AVERSANO ET AL.: "A chimeric IgG4 monoclonal antibody directed against CD18 reduces infarct size in a primate model of myocardial ischemia and reperfusion." see abstract ---	1-17
A	STROKE, vol. 23, no. 5, May 1992, DALLAS, TX, USA, pages 712-718, XP002036513 E. MORI ET AL.: "Inhibition of polymorphonuclear leukocyte adherence suppresses no-reflow after focal cerebral ischemia in baboons." cited in the application see abstract ---	1-17
A	STROKE, vol. 23, no. 1, January 1992, DALLAS, TX, USA, page 152 XP002036514 M. BEDNAR ET AL.: "IB4, a monoclonal antibody against the CD18 adhesion complex of leukocytes, attenuates intracranial hypertension in a rabbit stroke model." cited in the application see abstract 68 ---	1-17
A	PROTEINS: STRUCTURE, FUNCTION, AND GENETICS, vol. 18, no. 1, January 1994, NEW YORK, NY, USA, pages 49-62, XP000578098 C. EIGENBROT ET AL.: "X-ray structures of fragments from binding and nonbinding versions of a humanized anti-CD18 antibody: Structural indications of the key role of VH residues 59 to 65." see the whole document ---	3-5,11, 12
A	WO 94 04679 A (GENENTECH, INC.) 3 March 1994 see figures 6,7 -----	5,11

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 97/00492

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: 1-14 because they relate to subject matter not required to be searched by this Authority, namely:  
**Remark:** Although claim(s) 1-14 is(are) directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2.  Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- The additional search fees were accompanied by the applicant's protest.  
 No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Internal Application No

PCT/US 97/00492


Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9404679 A	03-03-94	AU 675916 B AU 2250992 A EP 0590058 A JP 6508267 T CA 2103059 A WO 9222653 A AU 5083193 A	27-02-97 12-01-93 06-04-94 22-09-94 15-12-92 23-12-92 15-03-94
-----			



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>A61K 39/395, A61J 1/00</b>		A3	(11) International Publication Number: <b>WO 97/26912</b>
			(43) International Publication Date: <b>31 July 1997 (31.07.97)</b>
(21) International Application Number: <b>PCT/US97/00492</b>		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: <b>11 January 1997 (11.01.97)</b>			
(30) Priority Data: 08/589,982                    23 January 1996 (23.01.96)                    US			
(71) Applicants: GENENTECH, INC. (US/US); 460 Point San Bruno Boulevard, South San Francisco, CA 94080-4990 (US). UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE (US/US); 85 South Prospect Street, Burlington, VT 05405-0160 (US).		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	
(72) Inventors: BEDNAR, Martin, M.; 33 Bartlett Bay Road, South Burlington, VT 05403 (US). GROSS, Cordell, E.; 1001 Dorset Street, South Burlington, VT 05403 (US). THOMAS, G., Roger; 812 Park Avenue, Burlingame, CA 94010 (US).		(88) Date of publication of the international search report: <b>9 October 1997 (09.10.97)</b>	
(74) Agents: HASAK, Janet, E. et al.; Genentech, Inc., 460 Point San Bruno Boulevard, South San Francisco, CA 94080-4990 (US).			

(54) Title: ANTI-CD18 ANTIBODIES FOR USE AGAINST STROKE



## (57) Abstract

A method for improving clinical outcome in focal ischemic stroke in a mammal by increasing cerebral blood flow and/or reducing infarct size is described which involves administering an effective amount of an anti-CD18 antibody to the mammal, in the absence of removal of the arterial obstruction.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	L1	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

## ANTI-CD 18 ANTIBODIES FOR USE AGAINST STROKE

This invention was made with United States government support under grant NS31008 and NS28708 awarded by the National Institutes of Health. The United States government has certain rights in the invention.

### **BACKGROUND OF THE INVENTION**

#### **5 Field of the Invention**

This invention relates generally to the use of anti-CD18 antibodies for treating stroke. In particular, it relates to the use of anti-CD18 antibodies for improving clinical outcome by increasing cerebral blood flow and/or reducing infarct size in focal ischemic stroke caused by obstruction of a main cerebral artery.

#### **Description of Related Art**

10 Stroke is a general term for acute brain damage resulting from disease of blood vessels. This presents a serious problem to society, with about 500,000 people dying from or becoming permanently disabled by stroke in the United States each year. Stroke can be classified into two main categories: hemorrhagic stroke (resulting from leakage of blood outside of the normal blood vessels) and ischemic stroke (cerebral ischemia due to lack of blood supply); this application is primarily concerned with the latter.

15 The three main mechanisms of ischemic stroke are thrombosis, embolism and systemic hypoperfusion (with resultant ischemia and hypoxia). In each of these types of stroke, the area of the brain that dies as a result of the lack of blood supply thereto is called an infarct. Obstruction of a cerebral artery resulting from a thrombus which has built up on the wall of a brain artery is generally called *cerebral thrombosis*. In *cerebral embolism*, the occlusive material blocking the cerebral artery arises downstream in the circulation (e.g. an embolus is carried 20 to the cerebral artery from the heart). Because it is difficult to discern whether a stroke is caused by thrombosis or embolism, the term *thromboembolism* is used to cover both these types of stroke. *Systemic hypoperfusion* may arise as a consequence of decreased blood levels, reduced hematocrit, low blood pressure or inability of the heart to pump blood adequately.

When symptoms of stroke last less than 24 hours and the patient recovers completely, the patient is said 25 to have undergone a transient ischemic attack (TIA). The symptoms of TIA are a temporary impairment of speech, vision, sensation or movement. Because a TIA is often thought to be a prelude to full-scale stroke, patients having suffered a TIA are candidates for prophylactic stroke therapy with anticoagulation agents (e.g., coumarin and heparin) or antiplatelet agents (such as aspirin and ticlopidine) for example.

30 Thrombolytic agents, such as tissue plasminogen activator (t-PA), have been used in the treatment of thromboembolic stroke. These molecules function by lysing the thrombus causing the ischemia. Such drugs are believed to be most useful if administered as soon as possible after acute stroke (preferably within 3 hours) in order to at least partially restore cerebral blood flow in the ischemic region and to sustain neuronal viability. In that such drugs exacerbate bleeding, their use in hemorrhagic stroke is contra-indicated.

A family of adhesion glycoproteins present on leukocytes is called the *integrin* family. This integrin 35 family includes LFA-1 (CD11a/CD18), Mac-1 (CD11b/CD18) and p150,95 (CD11c/CD18). A further member of this family CD11d/CD18 has recently been reported. Danilenko *et al.*, *J. Immunol.* 155:35-44 (1995). Each of these heterodimers has a unique  $\alpha$ -chain (CD11a, b, c or d) and the invariant  $\beta$ -chain (CD18). CD18 integrins located on leukocytes may bind to intercellular adhesion molecule-1 (ICAM-1) which is expressed on vascular endothelium and other cells, thereby mediating leukocyte adhesion and transendothelial migration.

It has been noted that CD11a and CD18 are upregulated in leukocytes from patients who have undergone ischemic stroke or a TIA. Kim *et al.*, *J. Neurolog. Sci.* 128(1):45-50 (1995). Schroeter *et al.*, *J. Neuroimmunology* 55(2):195-203 (1994) found that increased expression of ICAM-1 on vessels and leukocytes occurred following cerebral ischemia induced by permanent occlusion of the middle cerebral artery (MCA) in the rat.

The role of cell adhesion molecules in brain injury following transient MCA occlusion in the rat has been studied (Matsuo *et al.*, *Brain Research* 656:344-352 (1994)). Matsuo *et al.* inserted a nylon thread from the lumen of the external carotid artery (ECA) to that of the right internal carotid artery (ICA) in order to occlude the origin of the right MCA. The occlusion was transient; after 1 hour, the nylon thread was removed to allow complete reperfusion of the ischemic area via the right common carotid artery (CCA). Anti-CD11a (WT1), anti-CD18 (WT3) and anti-ICAM-1 (1A29) antibodies were administered before ischemia and immediately after reperfusion. These researchers found that treatment with individual antibodies against cell adhesion molecules reduced edema formation, infarct size and neutrophil accumulation following reperfusion.

Others have investigated the effects of antibodies against cell adhesion molecules in such transient stroke models. Zhang *et al.*, *Brain Research* 698:79-85 (1995) studied the effects of anti-CD11b and anti-CD18 monoclonal antibodies in ischemia/reperfusion injury, wherein the antibodies were administered upon and after transient MCA occlusion (the origin of the MCA was transiently blocked with a surgical nylon filament). Mori *et al.*, *Stroke* 23(5): 712-718 (1992) studied the effects of the anti-CD18 IB4 antibody in their baboon model of reversible MCA occlusion. In this model, arterial obstruction was achieved by inflating an extrinsic MCA balloon to 100ul. Reperfusion occurred following balloon deflation. See, also, Chopp *et al.*, *Stroke* 25(4):869-876 (1994) and Chen *et al.*, *Annals of Neurology* 35(4): 458-463 (1994) concerning an anti-CD11b antibody in a transient cerebral ischemia model. Chopp *et al.*, and Chen *et al.*, advanced a surgical nylon suture into the ICA to block the origin of the MCA. Reperfusion was accomplished by withdrawing the suture until the tip cleared the ICA lumen.

Takeshima *et al.*, *Stroke*, 23(2):247-252 (1992) found that the anti-CD18 antibody 60.3 did not afford protection from severe focal ischemia and reperfusion in a transient focal cerebral ischemia model in cats. Takeshima *et al.* used a microvascular clip to occlude the MCA and occluded CCAs by tightening previously placed ligatures.

Lindsberg *et al.*, *J. Neurosurg.* 82:269-277 (1995) subjected rabbits to severe spinal cord ischemia (by inflating the balloon of a catheter tip which had been introduced in the abdominal aorta) followed by 30 minutes of reperfusion at which time either: (1) vehicle, (2) anti-CD18 antibody, or (3) anti-CD18 antibody and platelet-activating factor (PAF) antagonist were administered to the animals. Recovery of motor function was improved by the anti-CD18 antibody, but no further improvement was induced by the PAF antagonist.

It has been observed that while an anti-CD18 antibody reduced neurologic deficits in the reversible spinal cord model (involving a snare ligature occluding device), it was unable to do so in an irreversible microsphere model. Clark *et al.*, *Stroke* 22(7): 877-883 (1991). Clark *et al.* conclude that leukocytes potentiate their effect in central nervous system injury via reperfusion injury. With respect to anti-CD11b antibodies, Chopp *et al.*, *Stroke* 25(1):267 (1994) report that benefit from administration of such antibodies was observed under conditions of transient, but not permanent, MCA occlusion in rats. See, also, Jiang *et al.*, *Neuroscience*

*Research Communications* 15(2):85-93 (1994). Clark *et al.*, *J. Neurosurg.* 75(4):623-627 (1991) also observe that while anti-ICAM-1 produced a significant reduction in neurological deficits in the reversible spinal cord ischemia model, such therapeutic benefit was not seen in the irreversible brain ischemia model. Similar findings in relation to anti-ICAM-1 antibodies have also been reported by Zhang *et al.*, *Stroke* 26(8):1438-1442 (1995).

5        Bowes *et al.*, *Neurology* 45:815-819 (1995) evaluated the ability of monoclonal antibodies directed against ICAM-1 and CD18 to enhance the efficacy of thrombolysis in a rabbit cerebral embolism stroke model. In this model, numerous small blood clots (formed by fragmenting a clot with a tissue homogenizer) were injected into the rabbit's carotid circulation in order to achieve embolization. Neurologic function in each animal was evaluated 18 hours following embolization on a three point scale: (1) normal activity; (2) abnormal activity; 10 or (3) death. The amount of clot necessary to produce permanent neurologic damage in 50% of the rabbits ( $ED_{50}$ ) was determined for each treatment group. Bowes *et al.*, found that when administration of anti-CD18 or anti-ICAM-1 was delayed until 15 or 30 minutes after embolization, a statistically significant improvement in neurologic function was *not* observed. See also Bowes *et al.*, *Experimental Neurology* 119(2):215-219 (1993) in relation to earlier work by this group regarding anti-ICAM-1 and t-PA in their rabbit cerebral embolism stroke model.

15      Bednar *et al.*, *Stroke* 23(1):152 (1992) describe a rabbit model of thromboembolic stroke wherein the arterial occlusion (an autologous blood clot delivered to the anterior cerebral circulation) is not removed during the experiment. Rabbits received either anti-CD18 antibody IB4 (1mg/kg), or vehicle, 30 minutes following the thromboembolic event. Following embolization, the animals were studied for a total of 4 hours, including an initial 45 minutes of systemic hypotension. No statistically significant difference in cerebral blood flow (CBF) or infarct size between IB4 and vehicle treated animals was seen. However, IB4 did attenuate intracranial hypertension in this model.

20      It is an object of the present invention to provide a method for improving clinical outcome in acute ischemic stroke by increasing cerebral blood flow and/or reducing infarct size. Furthermore, it is an object of the invention to provide an alternative to thrombolytic therapy for treating thromboembolic stroke, particularly where thrombolytic therapy has been unsuccessful or is contra-indicated, as is the case where the patient to be treated is taking aspirin, or where the time delay from the onset of stroke to diagnosis is such that thrombolytic therapy is not recommended. Other objects will be apparent from the description which follows.

#### SUMMARY OF THE INVENTION

25      This application is based on the unexpected finding that anti-CD18 antibodies can lead to a significant increase in cerebral blood flow and/or reduction in brain infarct size in focal ischemic stroke, in the absence of removal of the arterial obstruction.

Accordingly, the invention provides a method for treating stroke in a mammal (e.g. focal ischemic stroke caused by obstruction of a main cerebral artery) which comprises the step of administering an amount of 30 CD18 antagonist and/or CD11b antagonist to the mammal which is effective for increasing cerebral blood flow and/or reducing cerebral infarct size in the mammal. In the method, the arterial obstruction (generally a single thrombus or embolus) is not removed by mechanical means (e.g. by surgically removing the obstruction) or chemical means (e.g. by using a thrombolytic agent to dissolve the arterial obstruction). Furthermore, the

recipient of the CD18 or CD11b antagonist is not subjected to extraneous systemic hypotension (e.g., via controlled exsanguination) during the method as was the case in Bednar *et al.*, *Stroke* 23(1):152 (1992).

Preferably the antagonist is an anti-CD18 antibody, such as a humanized F(ab')<sub>2</sub> fragment. Conveniently, the antagonist is administered to the mammal in the form of a pharmaceutically acceptable formulation, such as those elaborated in more detail herein.

The preferred mode of administration of the antagonist is by bolus intravenous dosage. In certain embodiments of the invention, the antagonist may be administered at least once a time between about 15 minutes to about 20 hours and preferably between about 30 minutes to about 12 hours from the onset of focal ischemic stroke. Single or multiple dosages may be given. Alternatively, or in addition, the antagonist may be administered via continuous infusion.

In another aspect, the invention relates to a method for treating ischemic stroke caused by systemic hypoperfusion or hypoxia in a mammal (e.g. resulting from cardiac arrest or drowning) which comprises the step of administering a therapeutically effective amount of CD11b antagonist and/or CD18 antagonist to the mammal. The preferred antagonist for use in this method is an anti-CD18 antibody. Preferably, the method results in an increase in cerebral blood flow and a decrease in infarct size resulting from the systemic hypoperfusion.

In yet another embodiment, the invention provides a method for increasing cerebral blood flow and/or reducing infarct size in focal ischemic stroke caused by obstruction of a main cerebral artery which comprises the step of administering a therapeutically effective amount of CD18 and/or CD11b antagonist to the mammal at least once at a time more than 15 mins (e.g. more than 30 mins) and preferably less than 24 hours from the onset of focal ischemic stroke in the mammal. In the method, the mammal being treated is not subjected to extraneous systemic hypotension as described in Bednar *et al.*, *Stroke* 23(1):152 (1992). Preferably the antagonist is an anti-CD18 antibody which is administered at least once at a time between about 30 minutes to about 12 hours from the onset of focal ischemic stroke.

According to the method of the previous paragraph, a therapeutically effective amount of a thrombolytic agent (such as t-PA) may be co-administered to the mammal either before, after, or simultaneously with, the CD11b or CD18 antagonist. Preferably, the antagonist is administered to the mammal prior to administration of the thrombolytic agent. According to this method, the thrombolytic agent may be administered to the mammal more than about 3 hours after the onset of ischemic stroke (e.g., at least once within about 3-8 hours and preferably within about 3-5 hours from the onset of stroke). The thrombolytic agent may be administered by one or more bolus doses or by continuous infusion, for example.

The invention also provides articles of manufacture and kits for use in the above methods.

#### Brief Description of the Drawings

Fig. 1 is a bar graph depicting brain infarct size (% hemisphere infarcted) in embolized rabbits following treatment with MHM23 (anti-CD18) and t-PA (n=5); MHM23 alone (n=5); t-PA alone (n=10) or saline solution control (n=10) as described in Example 1 (mean +/- standard error of the mean).

Fig. 2 depicts regional cerebral blood flow (CBF; cc/100gm/min) over time in embolized rabbits following treatment with MHM23 (anti-CD18) and t-PA (n=5); MHM23 alone (n=5); t-PA alone (n=10) or saline solution control (n=10) as described in Example 1. MHM23 or saline solution control was administered

1 hour following embolization. t-PA or saline solution control was administered by continuous infusion over hours 3-5 following embolization (mean +/- standard error of the mean).

Fig. 3 illustrates intracranial pressure (ICP; mm Hg) in embolized rabbits following treatment with MHM23 (anti-CD18) and t-PA (n=5); MHM23 alone (n=5); t-PA alone (n=10) or saline solution control (n=10) 5 as described in Example 1. MHM23 or saline solution control was administered 1 hour following embolization. t-PA or saline solution control was administered by continuous infusion over hours 3-5 following embolization (mean +/- standard error of the mean).

Figs. 4A-B depict an alignment of the relevant portions of the consensus amino acid sequences of the 10 human IgG<sub>1</sub> CH1 domain (SEQ ID NO: 1), the human IgG<sub>2</sub> CH1 domain (SEQ ID NO: 2), the human IgG<sub>3</sub> CH1 domain (SEQ ID NO: 3), the human IgG<sub>4</sub> CH1 domain (SEQ ID NO: 4), the human κ C<sub>L</sub> domain (SEQ ID NO: 5), and the human λ C<sub>L</sub> domain (SEQ ID NO: 6), in alignment with the FabvIb variant derived from an anti-CD18 antibody (SEQ ID NO: 7). In Figs. 4A-B, amino acid residues and/or positions of interest and of most importance for use as salvage receptor binding epitopes within the sequence of FabvIb (*i.e.*, SEQ ID NOS: 8 and 9) are designated by underlining and asterisks, respectively.

#### 15 Detailed Description of the Preferred Embodiments

##### I. Definitions

"Focal ischemic stroke" is defined herein as damage to the brain caused by interruption of the blood supply to a region thereof. The focal ischemic stroke of interest herein is generally caused by obstruction of any one or more of the "main cerebral arteries" (*e.g.*, middle cerebral artery, anterior cerebral artery, posterior 20 cerebral artery, internal carotid artery, vertebral artery or basilar artery), as opposed to secondary arteries or arterioles. The "arterial obstruction" is generally a single embolus or thrombus. Hence, focal ischemic stroke as defined herein is distinguished from the cerebral embolism stroke model of Bowes *et al.*, *Neurology* 45:815-819 (1995) in which a plurality of clot particles occlude secondary arteries or arterioles.

The expression "in the absence of removal of the arterial obstruction" when used throughout this 25 application means that the arterial obstruction is essentially not removed by mechanical means (for example, by physically removing the obstruction as described in the transient stroke models described above) or by chemical means (such as removal of a thrombus or embolus using a thrombolytic agent; see, *e.g.*, Bowes *et al.*, *Neurology* 45:815-819 (1995)) prior to a therapeutic benefit achieved by administration of the CD18 or CD11b antagonist (*i.e.*, the increase in cerebral blood flow and/or the reduction in infarct size). However, this term would 30 encompass situations wherein the arterial obstruction is slightly reduced in size as a consequence of endogenous thrombolytic molecules dissolving part of the thrombus/embolus, provided that at least some (*e.g.*, about 50% and preferably about 80%) of the arterial obstruction remains intact following any such size reduction.

By "increasing cerebral blood flow or reducing infarct size" is meant the act of improving clinical outcome by inducing a statistically or physiologically significant increase in cerebral blood flow and/or a 35 statistically or physiologically significant reduction in infarct size in a treated mammal relative to an untreated mammal as determined using techniques which are well known in the art, such as vascular imaging, for example. Preferably cerebral blood flow as determined 2-4 hours after administration of the antagonist is increased by at least 30% and preferably at least 50% relative to an untreated mammal. Desirably, infarct size measured 48

hours after administration of the antagonist will be 20% less and preferably 50% less than that of an untreated mammal.

The term "CD18 antagonist" when used herein refers to a molecule which binds to CD18 (preferably human CD18) and inhibits or substantially reduces a biological activity of CD18. Normally, the antagonist will 5 block (partially or completely) the ability of a cell (e.g. a neutrophil) expressing the CD18 subunit at its cell surface to bind to endothelium. Non-limiting examples of CD18 antagonists include antibodies, proteins, peptides, glycoproteins, glycopeptides, glycolipids, polysaccharides, oligosaccharides, nucleic acids, bioorganic molecules, peptidomimetics, pharmacological agents and their metabolites, transcriptional and translation control sequences, and the like. In the preferred embodiment of the invention, the CD18 antagonist is an antibody.

10 Examples of anti-CD18 antibodies include MHM23 (Hildreth *et al.*, *Eur. J. Immunol.* 13:202-208 (1983)); M18/2 (IgG<sub>2a</sub>; Sanches-Madrid *et al.*, *J. Exp. Med.* 158:586 (1983)); H52 (American Type Culture Collection (ATCC) Deposit HB 10160); Mas191c and IOT18 (Vermot Desroches *et al.*, *Scand. J. Immunol.* 33:277-286 (1991)); and NA-8 (WO 94/12214). The preferred antibody is one which binds to the CD18 epitope to which either MHM23 or H52 binds. Preferably the antibody has a high affinity for the CD18 polypeptide. 15 In preferred embodiments, the antibody has an affinity for the CD18 antigen of about 4nM or less. Preferably, the affinity is about 3nM or less, and most preferably 1nM or less. In certain embodiments, the antibody may bind to a region in the extracellular domain of CD18 which associates with CD11b and the antibody may also dissociate  $\alpha$  and  $\beta$  chains (e.g. the antibody may dissociate the CD11b and CD18 complex as is the case for the MHM23 antibody).

20 The term "CD11b antagonist" when used herein refers to a molecule which binds to CD11b and inhibits or substantially reduces a biological activity of CD11b. Normally, the antagonist will block (partially or completely) the ability of a cell (e.g. a neutrophil) expressing the CD11b subunit at its cell surface to bind to endothelium. Non-limiting examples of CD11b antagonists include antibodies, proteins, peptides, glycoproteins, glycopeptides, glycolipids, polysaccharides, oligosaccharides, nucleic acids, bioorganic molecules, 25 peptidomimetics, pharmacological agents and their metabolites, transcriptional and translation control sequences, and the like. The preferred CD11b antagonist is an antibody, especially an anti-CD11b antibody which binds human CD11b. Exemplary CD11b antibodies include MY904 (US Patent 4,840,793); 1B6c (see Zhang *et al.*, *Brain Research* 698:79-85 (1995)); CBRN1/5 and CBRM1/19 (WO94/08620).

30 The term "antibody" is used in the broadest sense and specifically covers monoclonal antibodies, antibody compositions with polyepitopic specificity, bispecific antibodies, diabodies, and single-chain molecules, as well as antibody fragments (e.g., Fab, F(ab')<sub>2</sub>, and Fv), so long as they antagonize the biological activity of CD11b or CD18.

35 The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to conventional (polyclonal) antibody preparations which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. In addition to their specificity, the monoclonal antibodies are advantageous in that they are synthesized by the

hybridoma culture, uncontaminated by other immunoglobulins. The modifier "monoclonal" indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies to be used in accordance with the present invention may be made by the hybridoma 5 method first described by Kohler *et al.*, *Nature*, 256: 495 (1975), or may be made by recombinant DNA methods (see, e.g., U.S. Patent No. 4,816,567). The "monoclonal antibodies" may also be isolated from phage antibody libraries using the techniques described in Clackson *et al.*, *Nature*, 352:624-628 (1991) and Marks *et al.*, *J. Mol. Biol.*, 222:581-597 (1991), for example.

The monoclonal antibodies herein specifically include "chimeric" antibodies (immunoglobulins) in 10 which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity (U.S. Patent No. 4,816,567; Morrison *et al.*, *Proc. Natl. Acad. Sci. USA*, 81:6851-6855 (1984)).

"Humanized" forms of non-human (e.g., murine) antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')<sub>2</sub> or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin. For the most part, humanized antibodies are human immunoglobulins (recipient antibody) in which residues from 20 a complementary-determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity, and capacity. In some instances, Fv framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, humanized antibodies may comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. These modifications are 25 made to further refine and optimize antibody performance. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. For further 30 details, see Jones *et al.*, *Nature*, 321:522-525 (1986); Reichmann *et al.*, *Nature*, 332:323-329 (1988); and Presta, *Curr. Op. Struct. Biol.*, 2:593-596 (1992). The humanized antibody includes a Primatized<sup>TM</sup> antibody wherein the antigen-binding region of the antibody is derived from an antibody produced by immunizing macaque monkeys with the antigen of interest.

"Single-chain Fv" or "sFv" antibody fragments comprise the V<sub>H</sub> and V<sub>L</sub> domains of antibody, wherein 35 these domains are present in a single polypeptide chain. Generally, the Fv polypeptide further comprises a polypeptide linker between the V<sub>H</sub> and V<sub>L</sub> domains which enables the sFv to form the desired structure for antigen binding. For a review of sFv see Pluckthun in *The Pharmacology of Monoclonal Antibodies*, vol. 113, Rosenberg and Moore eds., Springer-Verlag, New York, pp. 269-315 (1994).

The term "diabodies" refers to small antibody fragments with two antigen-binding sites, which fragments comprise a heavy-chain variable domain ( $V_{H1}$ ) connected to a light-chain variable domain ( $V_{L1}$ ) in the same polypeptide chain ( $V_{H1} - V_{L1}$ ). By using a linker that is too short to allow pairing between the two domains on the same chain, the domains are forced to pair with the complementary domains of another chain and create 5 two antigen-binding sites. Diabodies are described more fully in, for example, EP 404,097; WO 93/11161; and Hollinger *et al.*, *Proc. Natl. Acad. Sci. USA*, 90: 6444-6448 (1993).

As used herein, the term "salvage receptor binding epitope" refers to an epitope of the Fc region of an IgG molecule (e.g., IgG<sub>1</sub>, IgG<sub>2</sub>, IgG<sub>3</sub>, and IgG<sub>4</sub>) that is responsible for increasing the *in vivo* serum half-life of the IgG molecule.

10 "Treatment" refers to both therapeutic treatment and prophylactic or preventative measures. Those in need of treatment include those already with the disorder as well as those in which the disorder is to be prevented. This application is mostly concerned with treating those individuals who have been diagnosed as having suffered acute ischemic stroke.

15 "Mammal" for purposes of treatment refers to any animal classified as a mammal, including humans, domestic and farm animals, and zoo, sports, or pet animals, such as dogs, horses, cats, cows, etc. Preferably, the mammal is human.

A "thrombolytic agent" is a molecule which breaks up or dissolves a thrombus. Exemplary thrombolytic agents include streptokinase, acylated plasminogen-streptokinase activator complex (APSAC), urokinase, single-chain urokinase-plasminogen activator (scu-PA), thrombinlike enzymes from snake venoms such as ancrod (Bell, 20 W. "Defibrinogenating enzymes" In Colman *et al.*, (eds): *Hemostasis and Thrombosis* Lippincott, Philadelphia (1987) p. 886), tissue plasminogen activator (t-PA) and biologically active variants of each of the above. The preferred thrombolytic agent is t-PA.

In the context of the present invention, the terms "tissue plasminogen activator" and "t-PA" are used 25 interchangeably and denote extrinsic (tissue type) plasminogen activator having at least two functional domains consisting of a protease domain that is capable of converting plasminogen to plasmin and an N-terminal region believed to be responsible for fibrin binding. These terms therefore include polypeptides containing these functional domains as part of the overall amino acid sequence, irrespective of their source and method of preparation (e.g. these terms cover vampire bat t-PAs as disclosed in EP 352,119). The terms "human tissue 30 plasminogen activator" and "human t-PA" are used interchangeably and denote wild-type human tissue plasminogen activator and functional derivatives thereof. Examples of t-PA functional derivatives include those molecules with extended half-life and improved fibrin specificity as disclosed in WO 93/24635; N-terminally truncated t-PA variants (see EP 382,174); and C84S t-PA described in Suzuki *et al.* *J. Cardiovasc. Pharmacol.* 22:834-840 (1993), for example.

## II. Modes for Carrying out the Invention

35 The invention provides a method for treating focal ischemic stroke, such as thromboembolic stroke. In particular, cerebral blood flow can be increased and/or infarct size can be reduced in focal ischemic stroke by administering an effective amount of a CD11b and/or CD18 antagonist to the mammal having suffered the stroke. In this method, the arterial obstruction is not removed prior to observation of the therapeutic benefit as defined herein, and as such the method does not require prior administration of a thrombolytic agent to the

mammal in order to remove an embolus/thrombus and thereby increase cerebral blood flow and/or reduce infarct size.

It is contemplated that the CD18 or CD11a antagonist of the present invention will be administered to a patient as soon as possible once the condition of acute ischemic stroke has been diagnosed or is suggested by 5 focal deficit on neurologic examination. Neurologic examination and, optionally, neuroimaging techniques such as computed tomography (CT) and magnetic resonance imaging (MRI) (including diffusion weighted imaging (DWI) and perfusion imaging (PI)); vascular imaging (e.g., duplex scanning and transcranial Doppler ultrasound and laser Doppler); angiography (e.g., computerized digital subtraction angiography (DSA) and MR angiography) as well as other invasive or non-invasive techniques are available for the diagnosis of acute 10 ischemic stroke.

Preferably, the CD18 or CD11a antagonist will be administered at least once or continuously at any time from immediately following to about 24 hours after the onset of stroke. In certain embodiments, the CD18 or CD11a antagonist is first administered to the patient at a time between about 15 minutes (or 30 minutes or 45 minutes) to about 5 hours (or 12 hours or 24 hours) from the onset of stroke. For example, the antagonist may 15 be first administered by bolus dosage as soon as stroke is diagnosed, followed by a subsequent bolus dosage of the antagonist (e.g. 5-24 hours after the initial bolus dosage).

The preferred antagonist for use in the above method is humanized H52 antibody (huH52), especially the huH52 F(ab')<sub>2</sub> antibody fragment.

The sequence of the heavy chain of the huH52 Fab is:

20 EVQLVESGGGLVQPGGSLRLSCATSGYTFTEYTMHWMRQAPGKGLEWVAGINPKNGGTSHNQRF  
MDRFTISVDKSTSTAYMQMNSLRAEDTAVYYCARWRGLNYGFDVRYFDVWGQGTLSVSSASTK  
GPSVFPLAPSSKSTSGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSVVTVT  
PSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHT (SEQ ID NO: 10).

The sequence of the light chain of the huH52 Fab is:

25 DIQMTQSPSSLSASVGDRVTITCRASQDINNYLNWYQQKPGKAPKLLIYYTSTLHSGVPSRFSGSGSG  
TDYTLTISSLQPEDFATYYCQQGNTLPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLL  
NNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSTLSKADYEKHKVYACEVTHQGL  
SSPVTKSFNRGEC (SEQ ID NO: 11).

In other embodiments, the full length IgG<sub>2</sub> huH52 antibody may be the molecule of choice. The heavy 30 chain of the full length IgG<sub>2</sub> huH52 antibody has the sequence:

EVQLVESGGGLVQPGGSLRLSCATSGYTFTEYTMHWMRQAPGKGLEWVAGINPKNGGTSHNQRF  
MDRFTISVDKSTSTAYMQMNSLRAEDTAVYYCARWRGLNYGFDVRYFDVWGQGTLSVSSASTK  
GPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSVVTVT  
35 SSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPCPAPPVAGPSVFLFPPPKDTLMSRTPEVT  
CVVVDVSHEDPEVQFNWYVDGMEVHNAAKTPREEQFNSTRVVSVLTVVHQDWLNGKEYKCKV  
SNKGLPAPIEKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNCQOPENN  
YKTTPPMLSDGSFFLYSKLTVDKSRWQQGNVFSCVMHEALHNHYTQKSLSLSPGK(SEQIDNO:12).

The light chain of the full length IgG<sub>2</sub> huH52 antibody has the sequence:

DIQMTQSPSSLSASVGDRVITCRASQDINNYLNWYQQKPGKAPKLLIYYTSTLHSGVPSRFSGSGSG  
TDYTLTISSLQPEDFATYYCQQGNTLPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLL  
NNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTTLSKADYEKHKVYACEVTHQGL  
SSPVTKSFNRGEC (SEQ ID NO: 13).

5 A description follows as to the production of the preferred antagonists (*i.e.* antibodies), long half-life antagonists, pharmaceutical formulations, modes for administration, as well as kits and articles of manufacture for use in the claimed methods. The description in relation to long half-life antagonists, pharmaceutical formulations and modes for administration is also relevant to the use of thrombolytic agents in certain embodiments of the invention.

10 **A. Antibody Preparation**

According to the preferred embodiment of the invention, the CD18 or CD11b antagonist is an antibody. Various antibodies which bind to CD18 and CD11b are available in the art. Furthermore, a description follows as to the production of anti-CD18 or anti-CD11b antibodies for use in the treatment of stroke as defined herein.

(i) *Polyclonal antibodies.*

15 Polyclonal antibodies are generally raised in animals by multiple subcutaneous (sc) or intraperitoneal (ip) injections of the relevant antigen and an adjuvant. It may be useful to conjugate the relevant antigen to a protein that is immunogenic in the species to be immunized, *e.g.*, keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, or soybean trypsin inhibitor using a bifunctional or derivatizing agent, for example, maleimidobenzoyl sulfosuccinimide ester (conjugation through cysteine residues), N-hydroxysuccinimide 20 (through lysine residues), glutaraldehyde, succinic anhydride,  $\text{SOCl}_2$ , or  $\text{R}^1\text{N}=\text{C}=\text{NR}$ , where R and  $\text{R}^1$  are different alkyl groups.

25 Animals are immunized against the antigen, immunogenic conjugates, or derivatives by combining 1 mg or 1  $\mu\text{g}$  of the peptide or conjugate (for rabbits or mice, respectively) with 3 volumes of Freund's complete adjuvant and injecting the solution intradermally at multiple sites. One month later the animals are boosted with 1/5 to 1/10 the original amount of peptide or conjugate in Freund's complete adjuvant by subcutaneous injection at multiple sites. Seven to 14 days later the animals are bled and the serum is assayed for antibody titer. Animals are boosted until the titer plateaus. Preferably, the animal is boosted with the conjugate of the same antigen, but conjugated to a different protein and/or through a different cross-linking reagent. Conjugates also can be made in recombinant cell culture as protein fusions. Also, aggregating agents such as alum are suitably used to 30 enhance the immune response.

(ii) *Monoclonal antibodies.*

35 Monoclonal antibodies are obtained from a population of substantially homogeneous antibodies, *i.e.*, the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Thus, the modifier "monoclonal" indicates the character of the antibody as not being a mixture of discrete antibodies.

For example, the monoclonal antibodies may be made using the hybridoma method first described by Kohler *et al.*, *Nature*, 256:495 (1975), or may be made by recombinant DNA methods (U.S. Patent No. 4,816,567).

In the hybridoma method, a mouse or other appropriate host animal, such as a hamster, is immunized as hereinabove described to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the protein used for immunization. Alternatively, lymphocytes may be immunized *in vitro*. Lymphocytes then are fused with myeloma cells using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding, *Monoclonal Antibodies: Principles and Practice*, pp.59-103 (Academic Press, 1986)).

The hybridoma cells thus prepared are seeded and grown in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, parental myeloma cells. For example, if the parental myeloma cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine (HAT medium), which substances prevent the growth of HGPRT-deficient cells.

Preferred myeloma cells are those that fuse efficiently, support stable high-level production of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. Among these, preferred myeloma cell lines are murine myeloma lines, such as those derived from MOPC-21 and MPC-11 mouse tumors available from the Salk Institute Cell Distribution Center, San Diego, California USA, and SP-2 cells available from the American Type Culture Collection, Rockville, Maryland USA. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies (Kozbor, *J. Immunol.*, 133:3001 (1984); Brodeur *et al.*, *Monoclonal Antibody Production Techniques and Applications*, pp. 51-63 (Marcel Dekker, Inc., New York, 1987)).

Culture medium in which hybridoma cells are growing is assayed for production of monoclonal antibodies directed against the antigen. Preferably, the binding specificity of monoclonal antibodies produced by hybridoma cells is determined by immunoprecipitation or by an *in vitro* binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA).

The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson *et al.*, *Anal. Biochem.*, 107:220 (1980).

After hybridoma cells are identified that produce antibodies of the desired specificity, affinity, and/or activity, the clones may be subcloned by limiting dilution procedures and grown by standard methods (Goding, *Monoclonal Antibodies: Principles and Practice*, pp.59-103 (Academic Press, 1986)). Suitable culture media for this purpose include, for example, D-MEM or RPMI-1640 medium. In addition, the hybridoma cells may be grown *in vivo* as ascites tumors in an animal.

The monoclonal antibodies secreted by the subclones are suitably separated from the culture medium, ascites fluid, or serum by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.

DNA encoding the monoclonal antibodies is readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). The hybridoma cells serve as a preferred source of such DNA. Once isolated, the DNA may be placed into expression vectors, which are then transfected into host cells such as *E. coli* cells, simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells.

Review articles on recombinant expression in bacteria of DNA encoding the antibody include Skerra *et al.*, *Curr. Opinion in Immunol.*, 5:256-262 (1993) and Plückthun, *Immunol. Revs.*, 130:151-188 (1992).

In a further embodiment, antibodies or antibody fragments can be isolated from antibody phage libraries generated using the techniques described in McCafferty *et al.*, *Nature*, 348:552-554 (1990). Clackson *et al.*,

- 5 *Nature*, 352:624-628 (1991) and Marks *et al.*, *J. Mol. Biol.*, 222:581-597 (1991) describe the isolation of murine and human antibodies, respectively, using phage libraries. Subsequent publications describe the production of high affinity (nM range) human antibodies by chain shuffling (Marks *et al.*, *Bio/Technology*, 10:779-783 (1992)), as well as combinatorial infection and *in vivo* recombination as a strategy for constructing very large phage libraries (Waterhouse *et al.*, *Nuc. Acids. Res.*, 21:2265-2266 (1993)). Thus, these techniques are viable
- 10 alternatives to traditional monoclonal antibody hybridoma techniques for isolation of monoclonal antibodies.

The DNA also may be modified, for example, by substituting the coding sequence for human heavy- and light-chain constant domains in place of the homologous murine sequences (U.S. Patent No. 4,816,567; Morrison, *et al.*, *Proc. Natl Acad. Sci. USA*, 81:6851 (1984)), or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide.

- 15 Typically such non-immunoglobulin polypeptides are substituted for the constant domains of an antibody, or they are substituted for the variable domains of one antigen-combining site of an antibody to create a chimeric bivalent antibody comprising one antigen-combining site having specificity for an antigen and another antigen-combining site having specificity for a different antigen.

20 Chimeric or hybrid antibodies also may be prepared *in vitro* using known methods in synthetic protein chemistry, including those involving crosslinking agents. For example, immunotoxins may be constructed using a disulfide-exchange reaction or by forming a thioether bond. Examples of suitable reagents for this purpose include iminothiolate and methyl-4-mercaptopbutyrimidate.

(iii) *Humanized and human antibodies.*

- 25 Methods for humanizing non-human antibodies are well known in the art. Generally, a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These non-human amino acid residues are often referred to as "import" residues, which are typically taken from an "import" variable domain. Humanization can be essentially performed following the method of Winter and co-workers (Jones-*et al.*, *Nature*, 321:522-525 (1986); Riechmann *et al.*, *Nature*, 332:323-327 (1988); Verhoeyen *et al.*, *Science*, 239:1534-1536 (1988)), by substituting rodent CDRs or CDR sequences for the corresponding 30 sequences of a human antibody. Accordingly, such "humanized" antibodies are chimeric antibodies (U.S. Patent No. 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.

35 The choice of human variable domains, both light and heavy, to be used in making the humanized antibodies is very important to reduce antigenicity. According to the so-called "best-fit" method, the sequence of the variable domain of a rodent antibody is screened against the entire library of known human variable-domain sequences. The human sequence which is closest to that of the rodent is then accepted as the human framework (FR) for the humanized antibody (Sims *et al.*, *J. Immunol.*, 151:2296 (1993); Chothia *et al.*, *J. Mol.*

*Biol.*, 196:901 (1987)). Another method uses a particular framework derived from the consensus sequence of all human antibodies of a particular subgroup of light or heavy chains. The same framework may be used for several different humanized antibodies (Carter *et al.*, *Proc. Natl. Acad. Sci. USA*, 89:4285 (1992); Presta *et al.*, *J. Immunol.*, 151:2623 (1993)).

5 It is further important that antibodies be humanized with retention of high affinity for the antigen and other favorable biological properties. To achieve this goal, according to a preferred method, humanized antibodies are prepared by a process of analysis of the parental sequences and various conceptual humanized products using three-dimensional models of the parental and humanized sequences. Three-dimensional immunoglobulin models are commonly available and are familiar to those skilled in the art. Computer programs  
10 are available which illustrate and display probable three-dimensional conformational structures of selected candidate immunoglobulin sequences. Inspection of these displays permits analysis of the likely role of the residues in the functioning of the candidate immunoglobulin sequence, i.e., the analysis of residues that influence the ability of the candidate immunoglobulin to bind its antigen. In this way, FR residues can be selected and combined from the recipient and import sequences so that the desired antibody characteristic, such as increased  
15 affinity for the target antigen(s), is achieved. In general, the CDR residues are directly and most substantially involved in influencing antigen binding:

20 Alternatively, it is now possible to produce transgenic animals (e.g., mice) that are capable, upon immunization, of producing a full repertoire of human antibodies in the absence of endogenous immunoglobulin production. For example, it has been described that the homozygous deletion of the antibody heavy-chain joining region ( $J_H$ ) gene in chimeric and germ-line mutant mice results in complete inhibition of endogenous antibody production. Transfer of the human germ-line immunoglobulin gene array in such germ-line mutant mice will result in the production of human antibodies upon antigen challenge. See, e.g., Jakobovits *et al.*, *Proc. Natl. Acad. Sci. USA*, 90:2551 (1993); Jakobovits *et al.*, *Nature*, 362:255-258 (1993); Brugermann *et al.*, *Year in Immuno.*, 7:33 (1993). Human antibodies can also be derived from phage- display libraries (Hoogenboom *et al.*, *J. Mol. Biol.*, 227:381 (1991); Marks *et al.*, *J. Mol. Biol.*, 222:581-597 (1991)).  
25

(iv) *Bispecific antibodies*

30 Bispecific antibodies (BsAbs) are antibodies that have binding specificities for at least two different epitopes. Exemplary BsAbs may bind to two different epitopes of the CD18 antigen or may bind both CD18 and CD11b. Such antibodies can be derived from full length antibodies or antibody fragments (e.g.  $F(ab')_2$  bispecific antibodies).

Methods for making bispecific antibodies are known in the art. Traditional production of full length bispecific antibodies is based on the coexpression of two immunoglobulin heavy chain-light chain pairs, where the two chains have different specificities (Millstein *et al.*, *Nature*, 305:537-539 (1983)). Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture  
35 of 10 different antibody molecules, of which only one has the correct bispecific structure. Purification of the correct molecule, which is usually done by affinity chromatography steps, is rather cumbersome, and the product yields are low. Similar procedures are disclosed in WO 93/08829, published 13 May 1993, and in Traunecker *et al.*, *EMBO J.*, 10:3655-3659 (1991).

According to a different and more preferred approach, antibody variable domains with the desired binding specificities (antibody-antigen combining sites) are fused to immunoglobulin constant domain sequences. The fusion preferably is with an immunoglobulin heavy chain constant domain, comprising at least part of the hinge, CH<sub>2</sub>, and CH<sub>3</sub> regions. It is preferred to have the first heavy-chain constant region (CH<sub>1</sub>) containing the site necessary for light chain binding, present in at least one of the fusions. DNAs encoding the immunoglobulin heavy chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are co-transfected into a suitable host organism. This provides for great flexibility in adjusting the mutual proportions of the three polypeptide fragments in embodiments when unequal ratios of the three polypeptide chains used in the construction provide the optimum yields. It is, however, possible to insert the coding sequences for two or all three polypeptide chains in one expression vector when the expression of at least two polypeptide chains in equal ratios results in high yields or when the ratios are of no particular significance.

In a preferred embodiment of this approach, the bispecific antibodies are composed of a hybrid immunoglobulin heavy chain with a first binding specificity in one arm, and a hybrid immunoglobulin heavy chain-light chain pair (providing a second binding specificity) in the other arm. It was found that this asymmetric structure facilitates the separation of the desired bispecific compound from unwanted immunoglobulin chain combinations, as the presence of an immunoglobulin light chain in only one half of the bispecific molecule provides for a facile way of separation. This approach is disclosed in WO 94/04690 published March 3, 1994. For further details of generating bispecific antibodies see, for example, Suresh *et al.*, *Methods in Enzymology*, 121:210 (1986). Using such techniques, a bispecific molecule which combines a thrombolytic agent such as t-PA and an anti-CD18 or anti-CD11b antibody can be prepared for use in the treatment of stroke as defined herein.

Bispecific antibodies include cross-linked or "heteroconjugate" antibodies. For example, one of the antibodies in the heteroconjugate can be coupled to avidin, the other to biotin. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells (US Patent No. 4,676,980), and for treatment of HIV infection (WO 91/00360, WO 92/200373, and EP 03089). Heteroconjugate antibodies may be made using any convenient cross-linking methods. Suitable cross-linking agents are well known in the art, and are disclosed in US Patent No. 4,676,980, along with a number of cross-linking techniques.

Techniques for generating bispecific antibodies from antibody fragments have also been described in the literature. The following techniques can also be used for the production of bivalent antibody fragments which are not necessarily bispecific. For example, Fab' fragments recovered from *E. coli* can be chemically coupled *in vitro* to form bivalent antibodies. See, Shalaby *et al.*, *J. Exp. Med.*, 175:217-225 (1992).

Various techniques for making and isolating bivalent antibody fragments directly from recombinant cell culture have also been described. For example, bivalent heterodimers have been produced using leucine zippers. Koštelny *et al.*, *J. Immunol.*, 148(5):1547-1553 (1992). The leucine zipper peptides from the Fos and Jun proteins were linked to the Fab' portions of two different antibodies by gene fusion. The antibody homodimers were reduced at the hinge region to form monomers and then re-oxidized to form the antibody heterodimers. The "diabody" technology described by Hollinger *et al.*, *Proc. Natl. Acad. Sci. USA*, 90:6444-6448 (1993) has provided an alternative mechanism for making bispecific/bivalent antibody fragments. The fragments comprise a heavy-chain variable domain ( $V_{H1}$ ) connected to a light-chain variable domain ( $V_{L1}$ ) by a linker which is too short to allow pairing between the two domains on the same chain. Accordingly, the  $V_{H1}$  and  $V_{L1}$  domains of one

fragment are forced to pair with the complementary  $V_L$  and  $V_H$  domains of another fragment, thereby forming two antigen-binding sites. Another strategy for making bispecific/bivalent antibody fragments by the use of single-chain Fv (sFv) dimers has also been reported. See Gruber *et al.*, *J. Immunol.*, 152:5368 (1994).

#### B. Long half-life antagonists

In certain embodiments of the invention, it is desirable to use CD18 or CD11b antagonists engineered to have an enhanced half-life in the serum of a mammal treated therewith. For example, this may be achieved by (i) incorporating a salvage receptor binding epitope of the Fc region of an IgG into the antagonist so as to increase its circulatory half-life, but without disrupting its biological activity or (ii) covalently binding a nonproteinaceous polymer to the antagonist. These exemplary techniques will be described briefly below:

10 (i) *Antagonist-salvage receptor binding epitope fusions.*

Incorporation of a salvage receptor binding epitope into the antagonist can take place by any means, such as by mutation of the appropriate region in the antagonist of interest to mimic the Fc region or by incorporating the epitope into a peptide tag that is then fused to the antagonist at either end or in the middle or by DNA or peptide synthesis.

15 A systematic method for preparing such an antagonist variant having an increased *in vivo* half-life comprises several steps. The first involves identifying the sequence and conformation of a salvage receptor binding epitope of an Fc region of an IgG molecule. Once this epitope is identified, the sequence of the antagonist of interest is modified to include the sequence and conformation of the identified binding epitope. After the sequence is mutated, the antagonist variant is tested to see if it has a longer *in vivo* half-life than that 20 of the original antagonist. If the antagonist variant does not have a longer *in vivo* half-life upon testing, its sequence is further altered to include the sequence and conformation of the identified binding epitope. The altered antagonist is tested for longer *in vivo* half-life, and this process is continued until a molecule is obtained that exhibits a longer *in vivo* half-life.

25 The salvage receptor binding epitope being thus incorporated into the antagonist of interest is any suitable such epitope as defined above, and its nature will depend, e.g., on the type of antagonist being modified. The transfer is made such that the antagonist of interest is still able to antagonize the biological activity of CD11b or CD18.

30 Where the antagonist of interest is an antibody, it contains an Ig domain or Ig-like domain and the salvage receptor binding epitope is placed so that it is located within this Ig domain or Ig-like domain. More preferably, the epitope constitutes a region wherein any one or more amino acid residues from one or two loops of the Fc domain are transferred to an analogous position of the Ig domain or Ig-like domain of the antibody. Even more preferably, three or more residues from one or two loops of the Fc domain are transferred. Still more preferred, the epitope is taken from the CH2 domain of the Fc region (e.g., of an IgG) and transferred to the CH1, 35 CH3, or  $V_H$  region, or more than one such region, of an Ig or to a Ig-like domain. Alternatively, the epitope is taken from the CH2 domain of the Fc region and transferred to the  $C_L$  region or  $V_L$  region, or both, of an Ig or to an Ig-like domain of the antagonist of interest.

For example, for purposes of discussing variants wherein the polypeptide of interest is an antibody, reference is made to Figs. 4A-B, which illustrates the relevant consensus primary structures of various Igs, i.e., human IgG<sub>1</sub> CH1 domain, human IgG<sub>2</sub> CH1 domain, human IgG<sub>3</sub> CH1 domain, human IgG<sub>4</sub> CH1 domain,

- human  $\kappa C_L$  domain, and human  $\lambda C_L$  domain, as well as the specific sequence for Fabv1b, a preferred anti-CD18 Fab variant herein. Further, Figs. 4A-B indicates the residues of Fabv1b that are of interest and of most importance. In a preferred embodiment, the residues of importance are those with an asterisk in Figs. 4A-B, i.e., in one loop of Fabv1b, MIS with a T residue one amino acid C-terminal to MIS, and in another loop of Fabv1b, 5 HQN with a D residue two amino acids C-terminal to HQN and a K residue one amino acid C-terminal to the D residue.

In one most preferred embodiment, the salvage receptor binding epitope comprises the sequence (5' to 3'): PKNSSMISNTP (SEQ ID NO: 8), and optionally further comprises a sequence selected from the group consisting of HQSLGTQ (SEQ ID NO: 14), HQNLSDGK (SEQ ID NO: 9), HQNISDGK (SEQ ID NO: 15), 10 or VISSH LGQ (SEQ ID NO: 16), particularly where the antagonist of interest is a Fab or F(ab')<sub>2</sub>.

(ii) *Antagonist-polymer conjugates.*

- The nonproteinaceous polymer of choice for this purpose is ordinarily a hydrophilic synthetic polymer, i.e., a polymer not otherwise found in nature. However, polymers which exist in nature and are produced by recombinant or *in vitro* methods are useful, as are polymers which are isolated from native sources. 15 Hydrophilic polyvinyl polymers fall within the scope of this invention, e.g. polyvinylalcohol and polyvinylpyrrolidone. Particularly useful are polyalkylene ethers such as polyethylene glycol (PEG); polyalkylenes such as polyoxyethylene, polyoxypropylene, and block copolymers of polyoxyethylene and polyoxypropylene (Pluronics); polymethacrylates; carbomers; branched or unbranched polysaccharides which comprise the saccharide monomers D-mannose, D- and L-galactose, fucose, fructose, D-xylose, L-arabinose, D-glucuronic acid, sialic acid, D-galacturonic acid, D-mannuronic acid (e.g. polymannuronic acid, or alginic acid), D-glucosamine, D-galactosamine, D-glucose and neuraminic acid including homopolysaccharides and heteropolysaccharides such as lactose, amylopectin, starch, hydroxyethyl starch, amylose, dextrane sulfate, dextran, dextrins, glycogen, or the polysaccharide subunit of acid mucopolysaccharides, e.g. hyaluronic acid; polymers of sugar alcohols such as polysorbitol and polymannitol; heparin or heparon. The polymer prior to cross-linking need not be, but preferably is, water soluble, but the final conjugate must be water soluble. In addition, the polymer should not be highly immunogenic in the conjugate form, nor should it possess viscosity 20 that is incompatible with intravenous infusion or injection if it is intended to be administered by such routes.

Preferably the polymer contains only a single group which is reactive. This helps to avoid cross-linking of protein molecules. However, it is within the scope herein to optimize reaction conditions to reduce cross-linking, or to purify the reaction products through gel filtration or chromatographic sieves to recover substantially 25 homogenous derivatives.

The molecular weight of the polymer may desirably range from about 100 to 500,000, and preferably is from about 1,000 to 20,000. The molecular weight chosen will depend upon the nature of the polymer and the degree of substitution. In general, the greater the hydrophilicity of the polymer and the greater the degree 35 of substitution, the lower the molecular weight that can be employed. Optimal molecular weights will be determined by routine experimentation.

The polymer generally is covalently linked to the antagonist though a multifunctional crosslinking agent which reacts with the polymer and one or more amino acid or sugar residues of the antagonist to be linked.

However, it is within the scope of the invention to directly crosslink the polymer by reacting a derivatized polymer with the hybrid, or *vice versa*.

Covalent binding to amino groups is accomplished by known chemistries based upon cyanuric chloride, carbonyl diimidazole, aldehyde reactive groups (PEG alkoxide plus diethyl acetal of bromoacetaldehyde; PEG plus DMSO and acetic anhydride, or PEG chloride plus the phenoxide of 4-hydroxybenzaldehyde, succinimidyl active esters, activated dithiocarbonate PEG, 2,4,5-trichlorophenylchloroformate or P-nitrophenylchloroformate activated PEG). Carboxyl groups are derivatized by coupling PEG-amine using carbodiimide.

Polymers are conjugated to oligosaccharide groups by oxidation using chemicals, e.g. metaperiodate, or enzymes, e.g. glucose or galactose oxidase, (either of which produces the aldehyde derivative of the carbohydrate), followed by reaction with hydrazide or amino derivatized polymers, in the same fashion as is described by Heitzmann *et al.*, *Proc. Natl Acad. Sci. USA* 71:3537-41 (1974) or Bayer *et al.*, *Methods in Enzymology* 62:310 (1979), for the labeling of oligosaccharides with biotin or avidin. Further, other chemical or enzymatic methods which have been used heretofore to link oligosaccharides are particularly advantageous because, in general, there are fewer substitutions than amino acid sites for derivatization, and the oligosaccharide products thus will be more homogenous. The oligosaccharide substituents also are optionally modified by enzyme digestion to remove sugars, e.g. by neuraminidase digestion, prior to polymer derivatization.

The polymer will bear a group which is directly reactive with an amino acid side chain, or the N- or C-terminus of the antagonist linked, or which is reactive with the multifunctional cross-linking agent. In general, polymers bearing such reactive groups are known for the preparation of immobilized proteins. In order to use such chemistries here, one should employ a water soluble polymer otherwise derivatized in the same fashion as insoluble polymers heretofore employed for protein immobilization. Cyanogen bromide activation is a particularly useful procedure to employ in crosslinking polysaccharides.

"Water soluble" in reference to the starting polymer means that the polymer or its reactive intermediate used for conjugation is sufficiently water soluble to participate in a derivatization reaction. "Water soluble" in reference to the polymer conjugate means that the conjugate is soluble in physiological fluids such as blood.

The degree of substitution with such a polymer will vary depending upon the number of reactive sites on the antagonist, whether all or a fragment of the antagonist is used, whether the antagonist is a fusion with a heterologous protein (e.g. anti-CD18 antibody fused to a salvage receptor binding epitope), the molecular weight, hydrophilicity and other characteristics of the polymer, and the particular antagonist derivatization sites chosen. In general, the conjugate contains about from 1 to 10 polymer molecules, while any heterologous sequence may be substituted with an essentially unlimited number of polymer molecules so long as the desired activity is not significantly adversely affected. The optimal degree of cross-linking is easily determined by an experimental matrix in which the time, temperature and other reaction conditions are varied to change the degree of substitution, after which the ability of the conjugates to function in the desired fashion is determined.

The polymer, e.g. PEG, is cross-linked by a wide variety of methods known *per se* for the covalent modification of proteins with nonproteinaceous polymers such as PEG.

The long half-life conjugates of this invention are separated from the unreacted starting materials by gel filtration. Heterologous species of the conjugates are purified from one another in the same fashion. The polymer also may be water-insoluble, as a hydrophilic gel.

### C. Pharmaceutical Formulations

Therapeutic formulations of the CD11b or CD18 antagonist are prepared for storage by mixing the antagonist having the desired degree of purity with optional physiologically acceptable carriers, excipients or stabilizers (*Remington's Pharmaceutical Sciences* 16th edition, Osol, A. Ed. (1980)), in the form of lyophilized formulations or aqueous solutions. Acceptable carriers, excipients or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate and other organic acids; antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin or immunoglobulins; amino acids such as glycine, glutamine, asparagine, histidine, arginine or lysine; monosaccharides, disaccharides and other carbohydrates including glucose, mannose, trehalose or dextrans; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and/or nonionic surfactants such as Tween, Pluronics or PEG.

The active ingredients may also be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacrylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules) or in macroemulsions. Such techniques are disclosed in *Remington's Pharmaceutical Sciences* 16th edition, Osol, A. Ed. (1980).

The formulations to be used for *in vivo* administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes, prior to or following lyophilization and reconstitution.

Sustained-release preparations may be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the CD18 or CD11b antagonist, which matrices are in the form of shaped articles, e.g. films, or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)), polylactides (U.S. Pat. No. 3,773,919), copolymers of L-glutamic acid and  $\gamma$  ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as the Lupron Depot<sup>TM</sup> (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid. While polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods. When encapsulated antibodies remain in the body for a long time, they may denature or aggregate as a result of exposure to moisture at 37°C, resulting in a loss of biological activity and possible changes in immunogenicity. Rational strategies can be devised for stabilization depending on the mechanism involved. For example, if the aggregation mechanism is discovered to be intermolecular S-S bond formation through thio-disulfide interchange, stabilization may be achieved by modifying sulphydryl residues, lyophilizing from acidic solutions, controlling moisture content, using appropriate additives, and developing specific polymer matrix compositions.

Sustained-release CD18 or CD11b antagonist compositions also include liposomally entrapped antagonists. Liposomes containing the CD18 or CD11b antagonist are prepared by methods known in the art, such as described in Epstein *et al.*, *Proc. Natl. Acad. Sci. USA*, 82:3688 (1985); Hwang *et al.*, *Proc. Natl. Acad. Sci. USA*, 77:4030 (1980); and U.S. Pat. Nos. 4,485,045 and 4,544,545. Ordinarily, the liposomes are the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol.% cholesterol,

the selected proportion being adjusted for the optimal CD18 or CD11b antagonist therapy. Liposomes with enhanced circulation time are disclosed in U.S. Patent No. 5,013,556.

#### D. Modes for Administration

The CD18 or CD11b antagonists of the invention are administered to a mammal, preferably a human, 5 in accord with known methods, such as intravenous administration as a bolus or by continuous infusion over a period of time, by intramuscular, intraperitoneal, intracerebrospinal, subcutaneous, intra-articular, intrasynovial, intrathecal, oral, topical, or inhalation routes. Intravenous administration of the antagonist is preferred.

The appropriate dosage of CD18 or CD11b antagonist will depend on the nature of the stroke to be treated, the severity and course of the stroke, whether the antagonist is administered for preventive or therapeutic 10 purposes, previous therapy, the patient's clinical history and response to the CD18 or CD11b antagonist, and the discretion of the attending physician. The CD18 or CD11b antagonist is suitably administered to the patient at one time or over a series of treatments and may be administered to the patient at any time from diagnosis onwards. For example, the antagonist may be administered at a time between about 15, 30 or 45 minutes to about 15 5 hours, 12 hours or 24 hours from the onset of stroke. In preferred embodiments, the initial dose is followed by at least one subsequent dose (e.g., from 5 to 24 hours after the initial dose). In certain situations, CD11b antagonist and CD18 antagonist are co-administered to the mammal.

Where the antagonist is an antibody, from about 100 $\mu$ g/kg to about 20mg/kg, and preferably from about 20 500 $\mu$ g/kg to about 5 mg/kg, and most preferably from about 1mg/kg to about 3mg/kg of the anti-CD18 or anti-CD11b antibody is an initial candidate dosage for administration to the patient, whether, for example, by one or more separate administrations, or by continuous infusion. However, other dosage regimens may be useful. The progress of this therapy is easily monitored by conventional techniques and assays elaborated herein.

#### E. Kits and Articles of Manufacture

In another embodiment of the invention, there are provided articles of manufacture and kits containing materials useful for improving clinical outcome in stroke by increasing cerebral blood flow and/or reducing 25 infarct size. The article of manufacture comprises a container with a label. Suitable containers include, for example, bottles, vials, and test tubes. The containers may be formed from a variety of materials such as glass or plastic. The container holds a composition which is effective for treating stroke as defined herein and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). The active agent in the composition is a CD11b or CD18 30 antagonist. The label on the container indicates that the composition is used for treating stroke as described above, and may also indicate directions for *in vivo* use, such as those described above.

The kit of the invention comprises the container described above and a second container comprising a pharmaceutically-acceptable buffer, such as phosphate-buffered saline, Ringer's solution and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, 35 diluents, filters, needles, syringes, and package inserts with instructions for use.

The following examples are offered by way of illustration and not by way of limitation. The disclosures of all citations in the specification are expressly incorporated herein by reference.

#### EXAMPLE

This study investigated the effect of anti-CD18 antibody (MHM23) and t-PA in a rabbit model of 40 thromboembolic stroke. In this model, a single blood clot is introduced into the middle cerebral and posterior

communicating arteries (which are "main cerebral arteries"). The arterial obstruction (i.e., the clot) remains in place throughout the experiment (unless it is enzymatically removed by t-PA). The following rabbit model is thought to correlate well with the physiological progression of thromboembolic stroke in humans.

#### Materials and Methods

5 The rabbit model of thromboembolic stroke used in the current study has been previously described in detail (Bednar *et al.*, *Neurol. Res.*, 16:129-132 (1994); Gross *et al.*, *Stroke*, 24:558-562 (1993); Kohut *et al.*, *Stroke*, 23:93-97 (1992); Wilson *et al.*, *Neurosurgery*, 31:929-934 (1992)). See, also, Gross *et al.*, *Neurosurgery*, 36(6):1172-1177 (1995).

Briefly, New Zealand white rabbits (Charles River, CA) (both males and females; 3.0-3.5kg) were  
10 anesthetized with the solution of ketamine (50mg/kg; Aveco Co., Fort Dodge, IA), acepromazine (20 mg, Aveco Co.), and xylazine (5 mg/kg; Mobay Corp., Shawnee, KS), a solution that was subsequently used to maintain sufficient anesthesia for painless surgery (as determined by responses to various physiological and autonomic stimuli, including mean arterial pressure and response to a paw being pinched). After an incision was made in  
15 the right femoral triangle to expose the femoral vein and artery, the femoral artery was cannulated with a PE-90 catheter (BD Co., Parsippany, NJ), to which was attached a platinum-iridium electrode. This catheter-electrode permitted the continuous measuring of mean arterial pressure and blood sampling for measurement of arterial blood gases (ABG) (pH, PCO<sub>2</sub>, PO<sub>2</sub>), hematocrit, and glucose and for determination of hydrogen washout to assess the rCBF by the hydrogen clearance technique (Young, *Stroke*, 11:552-564 (1980)). After the femoral vein was cannulated with PE-90 tubing for drug infusions, a midline scalp incision was made to expose the  
20 calvarium. Bilateral craniectomies were performed and the following were placed: 30-gauge platinum-iridium electrodes to monitor the regional cerebral blood flow (rCBF); a fiberoptic, epidural intracranial pressure (ICP) monitor (Princeton Medical Corp., Hudson, NH); and a temperature sensor (Yellow Springs Instruments, Yellow Springs, OH) to measure brain temperature. All cranial instrumentation was carefully fixed in place with fast-setting epoxy. Through a midline neck incision, the animal was tracheostomized and mechanically ventilated.  
25 Both depth and rate of ventilation were modified as needed to maintain ABGs within physiological range.

Throughout the experiment, the brain and core temperatures, mean arterial pressure, and ICP were continuously measured. Additionally, the following parameters were measured before embolization (baseline), at the time of embolization, and hourly after embolization: the rCBF, hematocrit, glucose, and ABG. The mean arterial pressures were kept between 50 and 60 mm Hg throughout the experiment. Fluids (Ringer's lactate or  
30 packed cells) were given intravenously as needed (approximately 2-4 ml/kg/h) to maintain euvolemia. Core and brain temperatures were maintained within 1°C of baseline by using heating blankets and heating lamps.

The autologous clot was prepared by mixing the whole blood (1 ml) with 50 mg of tin granules. The clot was introduced into the PE-90 tubing pretreated with thrombin and was allowed to mature at room temperature.

35 After tracheostomy, the region of the bifurcation of the common carotid artery was identified, followed by 30 to 60 minutes of equilibration, during which baseline values were obtained. All surgery was completed within 2 hours. Once all the baseline values were obtained, the proximal internal carotid artery and the distal common carotid artery were transiently isolated from the circulation. An arteriotomy was then performed, and the autologous clot embolus was delivered to the anterior circulation of the brain via a catheter advanced into

the proximal internal carotid artery. Once emboledized, both the proximal internal carotid artery and distal common carotid artery were again isolated from the circulation and an arteriorrhaphy was performed by using 10-0 interrupted nylon sutures. A Philip's dental x-ray machine was used to obtain a submental-vertex radiograph that verified placement of the tin-tagged clot. Embolized clots were noted within the middle cerebral and posterior communicating arteries.

t-PA or a saline solution (0.9% saline) was administered intravenously by continuous infusion from hours 3-5 after the embolization at a total dose of 6.3 mg/kg. MHM23 (2 mg/kg) was administered by bolus dosage 1 hour after embolization. In each instance, the experiment continued for 7 hours after embolization. Submental-vertex radiographs were obtained after embolization and at the end of the experiment. Immediately 10 after the embolization, the rCBF was measured again; the experiment was continued if the rCBF was  $\leq 15$  ml/100 g/ min in any of the three electrodes in the embolized hemisphere (Jones *et al.*, *J. Neurosurg.*, 54:773-782 (1981)).

At the end of the experiment, the animals were killed with an overdose of sodium pentobarbital (150 mg/kg), a procedure recognized as acceptable and painless, according to the euthanasia guidelines of the 15 American Veterinary Medical Association. Bilateral thoracotomies were performed in accordance with procedures outlined by the University of Vermont Institutional Animal Care and Utilization Committee. The brain was harvested rapidly and examined grossly for the presence and position of residual clot. The brain was cut into 2-mm slices in a bread-loaf fashion and incubated in triphenyltetrazolium chloride dye to define the size 20 of the brain infarct (Bose *et al.*, *Stroke*, 19:28-37 (1988)). This method has been shown to be an acceptable means of determining the size of a brain infarct in our rabbit model and correlates well with hematoxylin and eosin staining (Bednar *et al.*, *Neurol. Res.*, 16:129-132 (1994)). Each brain slice was carefully traced onto clear acetate sheets for later planimetric determination of the infarct size, for which an IBM image analyzer was used. The infarct size was determined according to the modification described by Lin *et al.*, *Stroke*, 24:117-121 (1993). 25 In this method, the region of the infarct is determined by subtracting the volume of the noninfarcted part of the embolized hemisphere from the entire volume of the nonembolized hemisphere. This modification takes into account that the volume of a brain infarct may be overestimated because of associated swelling.

The analysis of variance for repeated measures was used to analyze the hematocrit, glucose, ABG, rCBF, and ICP in the control and treated groups. If significance was noted, the values of these variables immediately before the t-PA and/or MHM23 administration were then compared by the Student's *t* test. When 30 necessary, the analysis of covariance was used to compare the control and treated groups. After a significant treatment-by-time interaction, individual contrasts were used to compare the treatment means at each time point; that is, if a significant treatment-by-time interaction was noted, the treatment effects were examined at each time point. The infarct size and specific gravities of the brain were compared (treated versus control) by the Student's *t* test. All the results were two-sided and were evaluated by using  $\alpha = 0.05$ .

35

## Results

The results of the above experiment are depicted in Figs. 1-3. As shown in Figs. 1 and 2, administration of anti-CD18 antibody alone, lead to a significant increase in cerebral blood flow as well as a significant reduction in infarct size relative to control. Fig. 3 shows that anti-CD18 antibody alone, t-PA alone, or a combination of these two agents tend to reduce intracranial pressure (ICP) at 6-7 hours. Furthermore, the

experiments show that anti-CD18 antibody is comparable with t-PA and improves the outcome of t-PA when given at 3-5 hours after installation of the clot into the cerebral circulation.

The increase in cerebral blood flow and the reduction in infarct size observed in the above experiments are thought to be predictive of an improvement in clinical outcome as measured by a standard stroke scale.

- 5 Accordingly, this application provides a method for improving clinical outcome in patients having suffered stroke as defined herein.

The model described in this example differs from that previously described in Bednar *et al.*, Stroke 23(1):152 (1992) in that the animals in the study were not subjected to extraneous systemic hypotension (by reducing the mean arterial pressure in the animal to 30 mmHg by controlled exsanguination). Also, the anti-  
10 CD18 antibody was given more than 30 minutes after the thromboembolic event and the dose was different.

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

(i) APPLICANT: Genentech, Inc.

University of Vermont and State Agricultural College

5 (ii) TITLE OF INVENTION: ANTI-CD18 ANTIBODIES IN STROKE

(iii) NUMBER OF SEQUENCES: 16

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Genentech, Inc.

(B) STREET: 460 Point San Bruno Blvd

(C) CITY: South San Francisco

(D) STATE: California

(E) COUNTRY: USA

(F) ZIP: 94080

15 (v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk

(B) COMPUTER: IBM PC compatible

(C) OPERATING SYSTEM: PC-DOS/MS-DOS

(D) SOFTWARE: WinPatin (Genentech)

20 (vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:

(B) FILING DATE:

(C) CLASSIFICATION:

25 (viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Lee, Wendy M.

(B) REGISTRATION NUMBER: 40,378

(C) REFERENCE/DOCKET NUMBER: P0987PCT

30 (ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: 415/225-1994

(B) TELEFAX: 415/952-9881

(C) TELEX: 910/371-7168

## (2) INFORMATION FOR SEQ ID NO:1:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 98 amino acids

(B) TYPE: Amino Acid

35 (D) TOPOLOGY: Linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

Ala	Ser	Thr	Lys	Gly	Pro	Ser	Val	Phe	Pro	Leu	Ala	Pro	Ser	Ser
1				5					10				15	

Lys	Ser	Thr	Ser	Gly	Gly	Thr	Ala	Ala	Leu	Gly	Cys	Leu	Val	Lys
40					20				25				30	

Asp	Tyr	Phe	Pro	Glu	Pro	Val	Thr	Val	Ser	Trp	Asn	Ser	Gly	Ala
					35				40				45	

Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser  
 50 55 60

Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser  
 65 70 75

5 Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser  
 80 85 90

Asn Thr Lys Val Asp Lys Arg Val  
 95 98

## (2) INFORMATION FOR SEQ ID NO:2:

- 10 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 98 amino acids  
 (B) TYPE: Amino Acid  
 (D) TOPOLOGY: Linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

15 Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser  
 1 5 10 15

Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys  
 20 25 30

20 Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala  
 35 40 45

Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser  
 50 55 60

Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Asn  
 65 70 75

25 Phe Gly Thr Gln Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser  
 80 85 90

Asn Thr Lys Val Asp Lys Thr Val  
 95 98

## (2) INFORMATION FOR SEQ ID NO:3:

- 30 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 98 amino acids  
 (B) TYPE: Amino Acid  
 (D) TOPOLOGY: Linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

35 Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser  
 1 5 10 15

Arg Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys  
 20 25 30

Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala

35	40	45
Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser		
50	55	60
Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser		
65	70	75
Leu Gly Thr Gln Thr Tyr Thr Cys Asn Val Asn His Lys Pro Ser		
80	85	90
Asn Thr Lys Val Asp Lys Arg Val		
95	98	

## 10 (2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 98 amino acids
  - (B) TYPE: Amino Acid
  - (D) TOPOLOGY: Linear

## 15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser		
1	5	10
		15

Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys		
20	25	30

Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala		
35	40	45

Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser		
50	55	60

Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser		
65	70	75

Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser		
80	85	90

Asn Thr Lys Val Asp Lys Arg Val		
95	98	

## 30 (2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 107 amino acids
  - (B) TYPE: Amino Acid
  - (D) TOPOLOGY: Linear

## 35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp		
1	5	10
		15

Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn		
20	25	30

	Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn		
	35	40	45
	Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp		
	50	55	60
5	Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser		
	65	70	75
	Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr		
	80	85	90
10	His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly		
	95	100	105
	Glu Cys		
	107		

## (2) INFORMATION FOR SEQ ID NO:6:

## (i) SEQUENCE CHARACTERISTICS:

- 15 (A) LENGTH: 105 amino acids  
 (B) TYPE: Amino Acid  
 (D) TOPOLOGY: Linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

20	Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser			
	1	5	10	15
	Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser			
	20	25	30	
	Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser			
	35	40	45	
25	Ser Pro Val Lys Ala Gly Val Glu Thr Thr Pro Ser Lys Gln			
	50	55	60	
	Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro			
	65	70	75	
30	Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His			
	80	85	90	
	Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser			
	95	100	105	

## (2) INFORMATION FOR SEQ ID NO:7:

## (i) SEQUENCE CHARACTERISTICS:

- 35 (A) LENGTH: 100 amino acids  
 (B) TYPE: Amino Acid  
 (D) TOPOLOGY: Linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Pro

1	5	10	15
Lys Asn Ser Ser Met Ile Ser Asn Thr Pro Ala Leu Gly Cys Leu			
20		25	30
5 Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser			
35		40	45
Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln			
50		55	60
Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro His			
65		70	75
10 Gln Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys			
80		85	90
Pro Ser Asn Thr Lys Val Asp Lys Arg Val			
95		100	

## (2) INFORMATION FOR SEQ ID NO:8:

- 15 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 11 amino acids  
 (B) TYPE: Amino Acid  
 (D) TOPOLOGY: Linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

20 Pro Lys Asn Ser Ser Met Ile Ser Asn Thr Pro			
1	5	10	11

## (2) INFORMATION FOR SEQ ID NO:9:

- 25 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 8 amino acids  
 (B) TYPE: Amino Acid  
 (D) TOPOLOGY: Linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

His Gln Asn Leu Ser Asp Gly Lys			
1	5	8	

## 30 (2) INFORMATION FOR SEQ ID NO:10:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 232 amino acids  
 (B) TYPE: Amino Acid  
 (D) TOPOLOGY: Linear

## 35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Glu Val Gln Leu Val Glu Ser Gly Gly Leu Val Gln Pro Gly			
1	5	10	15

Gly Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Tyr Thr Phe Thr			
20		25	30

Glu Tyr Thr Met His Trp Met Arg Gln Ala Pro Gly Lys Gly Leu  
                  35                        40                        45

Glu Trp Val Ala Gly Ile Asn Pro Lys Asn Gly Gly Thr Ser His  
                  50                        55                        60

5 Asn Gln Arg Phe Met Asp Arg Phe Thr Ile Ser Val Asp Lys Ser  
                  65                        70                        75

Thr Ser Thr Ala Tyr Met Gln Met Asn Ser Leu Arg Ala Glu Asp  
                  80                        85                        90

10 Thr Ala Val Tyr Tyr Cys Ala Arg Trp Arg Gly Leu Asn Tyr Gly  
                  95                        100                      105

Phe Asp Val Arg Tyr Phe Asp Val Trp Gly Gln Gly Thr Leu Val  
                  110                       115                      120

Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu  
                  125                       130                      135

15 Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly  
                  140                       145                      150

Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp  
                  155                       160                      165

Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val  
 20                 170                       175                      180

Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val  
                  185                       190                      195

Pro Ser Ser Ser Leu Gly Thr Gin Thr Tyr Ile Cys Asn Val Asn  
                  200                       205                      210

25 His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys  
                  215                       220                      225

Ser Cys Asp Lys Thr His Thr  
                  230                       232

## (2) INFORMATION FOR SEQ ID NO:11:

30 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 214 amino acids  
 (B) TYPE: Amino Acid  
 (D) TOPOLOGY: Linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

35 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val  
                  1                       5                       10                      15

Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Asn  
                  20                       25                      30

Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys

	35	40	45
	Leu Leu Ile Tyr Tyr Thr Ser Thr Leu His Ser Gly Val Pro Ser		
	50	55	60
5	Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile		
	65	70	75
	Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln		
	80	85	90
	Gly Asn Thr Leu Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu		
	95	100	105
10	Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro		
	110	115	120
	Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu		
	125	130	135
15	Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val		
	140	145	150
	Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu		
	155	160	165
	Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr		
	170	175	180
20	Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu		
	185	190	195
	Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn		
	200	205	210
25	Arg Gly Glu Cys		
	214		

## (2) INFORMATION FOR SEQ ID NO:12:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 450 amino acids

(B) TYPE: Amino Acid

30 (D) TOPOLOGY: Linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly
1				5				10				15		

Gly	Ser	Leu	Arg	Leu	Ser	Cys	Ala	Thr	Ser	Gly	Tyr	Thr	Phe	Thr
35				20				25				30		

Glu	Tyr	Thr	Met	His	Trp	Met	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu
				35			40				45			

Glu	Trp	Val	Ala	Gly	Ile	Asn	Pro	Lys	Asn	Gly	Gly	Thr	Ser	His
				50			55				60			

	Asn Gln Arg Phe Met Asp Arg Phe Thr Ile Ser Val Asp Lys Ser		
	65	70	75
	Thr Ser Thr Ala Tyr Met Gln Met Asn Ser Leu Arg Ala Glu Asp		
	80	85	90
5	Thr Ala Val Tyr Tyr Cys Ala Arg Trp Arg Gly Leu Asn Tyr Gly		
	95	100	105
	Phe Asp Val Arg Tyr Phe Asp Val Trp Gly Gln Gly Thr Leu Val		
	110	115	120
10	Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu		
	125	130	135
	Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly		
	140	145	150
	Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp		
	155	160	165
15	Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val		
	170	175	180
	Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val		
	185	190	195
20	Thr Ser Ser Asn Phe Gly Thr Gln Thr Tyr Thr Cys Asn Val Asp		
	200	205	210
	His Lys Pro Ser Asn Thr Lys Val Asp Lys Thr Val Glu Arg Lys		
	215	220	225
	Cys Cys Val Glu Cys Pro Pro Cys Pro Ala Pro Pro Val Ala Gly		
	230	235	240
25	Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met		
	245	250	255
	Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser		
	260	265	270
30	His Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Met		
	275	280	285
	Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn		
	290	295	300
	Ser Thr Phe Arg Val Val Ser Val Leu Thr Val Val His Gln Asp		
	305	310	315
35	Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly		
	320	325	330
	Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Thr Lys Gly Gln		
	335	340	345
	Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu		

	350	355	360
	Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe		
	365	370	375
5	Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro		
	380	385	390
	Glu Asn Asn Tyr Lys Thr Thr Pro Pro Met Leu Asp Ser Asp Gly		
	395	400	405
	Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp		
	410	415	420
10	Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu		
	425	430	435
	His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys		
	440	445	450

## (2) INFORMATION FOR SEQ ID NO:13:

15 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 214 amino acids  
 (B) TYPE: Amino Acid  
 (D) TOPOLOGY: Linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

20	Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val		
	1	5	10
	Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Asn		
	20	25	30
25	Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys		
	35	40	45
	Leu Leu Ile Tyr Tyr Thr Ser Thr Leu His Ser Gly Val Pro Ser		
	50	55	60
	Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile		
	65	70	75
30	Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln		
	80	85	90
	Gly Asn Thr Leu Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu		
	95	100	105
35	Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro		
	110	115	120
	Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu		
	125	130	135
	Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val		
	140	145	150

Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu  
155 160 165

Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr  
170 175 180

5 Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu  
185 190 195

Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn  
200 205 210

10 Arg Gly Glu Cys  
214

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7 amino acids
- (B) TYPE: Amino Acid
- (C) TOPOLOGY: Linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

His Gln Ser Leu Gly Thr Gln  
1 5 7

(2) INFORMATION FOR SEQ ID NO:15:

20 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 8 amino acids  
(B) TYPE: Amino Acid  
(D) TOPOLOGY: Linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

25 His Gln Asn Ile Ser Asp Gly Lys  
1 5 8

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 8 amino acids  
(B) TYPE: Amino Acid  
(D) TOPOLOGY: Linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

30 Val Ile Ser Ser His Leu Gly Gln  
1 5 8

## WHAT IS CLAIMED IS:

1. A method for treating focal ischemic stroke caused by obstruction of a main cerebral artery in a mammal comprising administering an amount of anti-CD18 antibody to the mammal which is effective for increasing cerebral blood flow or reducing infarct size, in the absence of removal of the arterial obstruction.
- 5 2. The method of claim 1 which increases cerebral blood flow and reduces infarct size in the mammal.
3. The method of claim 1 wherein the anti-CD18 antibody is an antibody fragment.
4. The method of claim 3 wherein the anti-CD18 antibody fragment is a F(ab')<sub>2</sub>.
5. The method of claim 1 wherein the anti-CD18 antibody is humanized.
- 10 6. The method of claim 1 wherein the anti-CD18 antibody is administered to the mammal by bolus dosage.
7. The method of claim 1 wherein the anti-CD18 antibody is administered intravenously.
8. The method of claim 1 wherein the anti-CD18 antibody is administered via continuous infusion.
- 15 9. The method of claim 1 wherein the anti-CD18 antibody is administered to the mammal at a time between about 15 minutes to about 20 hours from the onset of focal ischemic stroke.
10. The method of claim 9 wherein the anti-CD18 antibody is administered to the mammal at a time between about 45 mins to about 5 hours from the onset of focal ischemic stroke.
11. The method of claim 1 wherein the anti-CD18 antibody is humanized H52 antibody.
- 20 12. The method of claim 11 wherein the H52 antibody is a F(ab')<sub>2</sub>.
13. The method of claim 3 wherein the anti-CD18 antibody fragment is fused to a salvage receptor binding epitope.
14. The method of claim 1 wherein the mammal is a human.
15. An article of manufacture comprising:
  - 25 a container;
  - a label on said container; and
  - a composition comprising an active agent contained within said container; wherein the composition is effective for increasing cerebral blood flow or reducing infarct size in focal ischemic stroke caused by obstruction of a main cerebral artery, the label on said container indicates that the composition can be used for treating stroke and the active agent in said composition is an antagonist anti-CD18 antibody.
- 30 16. The article of manufacture of claim 15 further comprising instructions for administering the anti-CD18 antibody to a mammal to increase cerebral blood flow or reduce infarct size in focal ischemic stroke.

17. A kit, comprising:

a first container, a label on said container, and a composition comprising an active agent contained within said container; wherein the composition is effective for increasing cerebral blood flow or reducing infarct size in focal ischemic stroke caused by obstruction of a main cerebral artery, the label on said container indicates

5 that the composition can be used for treating stroke, and the active agent in said composition is an antagonist anti-CD18 antibody;

a second container comprising a pharmaceutically-acceptable buffer; and

instructions for using the anti-CD18 antibody to increase cerebral blood flow or reduce infarct size in focal ischemic stroke.

10

1 / 5






FIG. 1

SUBSTITUTE SHEET (RULE 26)

2 / 5

**FIG. 2****SUBSTITUTE SHEET (RULE 26)**

3 / 5

**FIG. 3****SUBSTITUTE SHEET (RULE 26)**

**hIgG<sub>1</sub>** Sequence of human IgG1 CH1 domain  
**hIgG<sub>2</sub>** Sequence of human IgG2 CH1 domain  
**hIgG<sub>3</sub>** Sequence of human IgG3 CH1 domain  
**hIgG<sub>4</sub>** Sequence of human IgG4 CH1 domain  
**humκ** Sequence of human kappa CL domain  
**humλ** Sequence of human lambda CL domain

---

114	128	139
<b>hIgG<sub>1</sub></b>	A S T K G P S V F P L A P S S K S T S G G T A A L	
<b>hIgG<sub>2</sub></b>	A S T K G P S V F P L A P C S R S T S E S T A A L	
<b>hIgG<sub>3</sub></b>	A S T K G P S V F P L A P C S R S T S G G T A A L	
<b>hIgG<sub>4</sub></b>	A S T K G P S V F P L A P C S R S T S E S T A A L	

108	122	131
<b>humκ</b>	R T V A A P S V F I F P P S D E Q L K S G T A S V	
<b>humλ</b>	Q P K A A P S V T L F P P S S E E L Q A N K A T L	

---

<b>Fabv1b</b>	A S T K G P S V F P L A P S P K N S S M I S N T P A L	
of interest		P K N S S M I S N T P

most important

---

\*\*\* \*

<b>hIgG<sub>1</sub></b>	G C L V K D Y F P E P V T V S W N S G A L T S	
<b>hIgG<sub>2</sub></b>	G C L V K D Y F P E P V T V S W N S G A L T S	
<b>hIgG<sub>3</sub></b>	G C L V K D Y F P E P V T V S W N S G A L T S	
<b>hIgG<sub>4</sub></b>	G C L V K D Y F P E P V T V S W N S G A L T S	

<b>humκ</b>	V C L L N N F Y P R E A K V Q W K V D N A L Q	
<b>humλ</b>	V C L I S D F Y P G A V T V A W K A D S S P V	

---

<b>Fabv1b</b>	G C L V K D Y F P E P V T V S W N S G A L T S	
---------------	---	--

<b>hIgG<sub>1</sub></b>	G V H T F P A V L Q S S G - - - L Y S L S S V	
<b>hIgG<sub>2</sub></b>	G V H T F P A V L Q S S G - - - L Y S L S S V	

## FIG. 4A

SUBSTITUTE SHEET (RULE 26)

5 / 5

hIgG <sub>3</sub>	G V H T F P A V L Q S S G - - -	L Y S L S S V
hIgG <sub>4</sub>	G V H T F P A V L Q S S G - - -	L Y S L S S V
humκ	S G N S Q E S V T E Q D S K D S T Y S L S S T	
humλ	K A G V E T T T P S K Q S N N - K Y A A S S Y	
<hr/>		
Fabv1b	G V H T F P A V L Q S S G - - -	L Y S L S S V
193                          200    203		
hIgG <sub>1</sub>	V T V P S S S L G T -	Q T Y I C N V N H K P S
hIgG <sub>2</sub>	V T V P S S S N F G T -	Q T Y T C N V D H K P S
hIgG <sub>3</sub>	V T V P S S S L G T -	Q T Y T C N V N H K P S
hIgG <sub>4</sub>	V T V P S S S L G T -	K T Y T C N V D H K P S
<hr/>		
181                          190		
humκ	L T L S K A D Y E K H K V Y A C E V T H Q G L	
humλ	L S L T P E Q W K S H R S Y S C Q V T H E G S	
<hr/>		
Fabv1b	V T V P H Q S L G T -	Q T Y I C N V N H K P S
of interest	H Q N L S D G K	
<hr/>		
most important	* * * * *	

hIgG <sub>1</sub>	N T K V D K R V - - -	
hIgG <sub>2</sub>	N T K V D K T V - - -	
hIgG <sub>3</sub>	N T K V D K R V - - -	
hIgG <sub>4</sub>	N T K V D K R V - - -	
<hr/>		
humκ	S S P V T K S F N R G E C	
humλ	T V E K T V A P T E C S	
<hr/>		
Fabv1b	N T K V D K R V - - -	

## FIG. 4B

**SUBSTITUTE SHEET (RULE 26)**

# INTERNATIONAL SEARCH REPORT

Intern. Appl. No.

PCT/US 97/00492

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC 6 A61K39/395 A61J1/00

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>AMERICAN JOURNAL OF PATHOLOGY, vol. 148, no. 1, January 1996, HAGERSTOWN, MD, USA, pages 241-248, XP002036510</p> <p>J. GARCIA ET AL.: "Effects of CD11b/18 monoclonal antibody on rats with permanent middle cerebral artery occlusion." see abstract</p> <p>---</p> <p>AMERICAN JOURNAL OF PHYSIOLOGY, vol. 270, no. 1 part 2, 1996, WASHINGTON, DC, USA, pages H53-H64, XP002036511</p> <p>R. PEREZ ET AL.: "Factors modifying protective effect of anti-CD18 antibodies on myocardial reperfusion injury in dogs." see abstract</p> <p>---</p> <p>-/-</p>	1-17
Y		1-17

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- 'A' document defining the general state of the art which is not considered to be of particular relevance
- 'E' earlier document but published on or after the international filing date
- 'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- 'O' document referring to an oral disclosure, use, exhibition or other means
- 'P' document published prior to the international filing date but later than the priority date claimed

'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

'&' document member of the same patent family

Date of the actual completion of the international search Date of mailing of the international search report

31 July 1997

26.08.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Nooij, F

## INTERNATIONAL SEARCH REPORT

Internal Application No

PCT/US 97/00492

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 25, no. 3, 1 March 1995, NEW YORK, NY, USA, pages 781-788, XP002036512 T. AVERSANO ET AL.: "A chimeric IgG4 monoclonal antibody directed against CD18 reduces infarct size in a primate model of myocardial ischemia and reperfusion." see abstract ---	1-17
A	STROKE, vol. 23, no. 5, May 1992, DALLAS, TX, USA, pages 712-718, XP002036513 E. MORI ET AL.: "Inhibition of polymorphonuclear leukocyte adherence suppresses no-reflow after focal cerebral ischemia in baboons." cited in the application see abstract	1-17
A	STROKE, vol. 23, no. 1, January 1992, DALLAS, TX, USA, page 152 XP002036514 M. BEDNAR ET AL.: "IB4, a monoclonal antibody against the CD18 adhesion complex of leukocytes, attenuates intracranial hypertension in a rabbit stroke model." cited in the application see abstract 68	1-17
A	PROTEINS: STRUCTURE, FUNCTION, AND GENETICS, vol. 18, no. 1, January 1994, NEW YORK, NY, USA, pages 49-62, XP000578098 C. EIGENBROT ET AL.: "X-ray structures of fragments from binding and nonbinding versions of a humanized anti-CD18 antibody: Structural indications of the key role of VH residues 59 to 65." see the whole document	3-5,11, 12
A	WO 94 04679 A (GENENTECH, INC.) 3 March 1994 see figures 6,7	5,11

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 97/00492

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: 1-14 because they relate to subject matter not required to be searched by this Authority, namely:  
**Remark:** Although claim(s) 1-14 is(are) directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2.  Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- The additional search fees were accompanied by the applicant's protest.  
 No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Internal Application No

PCT/US 97/00492

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9404679 A	03-03-94	AU 675916 B	27-02-97
		AU 2250992 A	12-01-93
		EP 0590058 A	06-04-94
		JP 6508267 T	22-09-94
		CA 2103059 A	15-12-92
		WO 9222653 A	23-12-92
		AU 5083193 A	15-03-94